<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - FANAPT - iloperidone tablet FANAPT -
iloperidone</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">FANAPT - iloperidone tablet<br>
FANAPT - iloperidone<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFANAPT%20%2D%20Iloperidone%20Tablet%20FANAPT%20%2D%20Iloperidone%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D33f60b40%2D3fca%2D11de%2D8f56%2D0002a5d5c51b%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-3.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-3.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-3.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-4.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-4.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-4.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
<h4 class="more closed">VIEW MORE</h4>
<div class="show-more">
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-5.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="2"><img id="zoom_3" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-5.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-5.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-6.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="3"><img id="zoom_4" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-6.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-6.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-7.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="4"><img id="zoom_5" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-7.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-7.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-8.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="5"><img id="zoom_6" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-8.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-8.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-9.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="6"><img id="zoom_7" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-9.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-9.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-10.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="7"><img id="zoom_8" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-10.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-10.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-11.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="8"><img id="zoom_9" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-11.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-11.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-12.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="9"><img id="zoom_10" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-12.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-12.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-13.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="10"><img id="zoom_11" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-13.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-13.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-14.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="11"><img id="zoom_12" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-14.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-14.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=fanapt-figure-15.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="12"><img id="zoom_13" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=fanapt-figure-15.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
src=
"image.cfm?type=img&amp;name=fanapt-figure-15.jpg&amp;setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a class="tip" rel="tooltip" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects."
href="#boxedwarning">Boxed Warnings</a></li>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22ILOPERIDONE%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=ILOPERIDONE"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=ILOPERIDONE"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ILOPERIDONE[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ILOPERIDONE/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ILOPERIDONE/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ILOPERIDONE/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ILOPERIDONE[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=ILOPERIDONE&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">43068-101-02, 43068-102-02, 43068-104-02,
43068-106-01, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id="item-code-s"><span>43068-106-02,
43068-108-01, 43068-108-02, 43068-110-02, 43068-112-02,
43068-113-03, 43068-113-04</span></span></div>
</li>
<li><strong>Packager:</strong> Vanda Pharmaceuticals Inc.</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated March 21, 2011</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;type=pdf&amp;name=33f60b40-3fca-11de-8f56-0002a5d5c51b"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;type=zip&amp;name=FANAPT"
target="_blank">XML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip"
rel="tooltip" href="#" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What
is this?)</a>
<div class="Warning toggle-content open"><a name=
"a687-0002a5d5c51bjt-bw" id="a687-0002a5d5c51bjt-bw"></a> <a name=
"section-1" id="section-1"></a>
<h1>WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
DEMENTIA-RELATED PSYCHOSIS</h1>
<p class="First"><span class="Bold">Elderly patients with
dementia-related psychosis treated with antipsychotic drugs are at
an increased risk of death. Analysis of seventeen
placebo-controlled trials (modal duration 10 weeks), largely in
patients taking atypical antipsychotic drugs, revealed a risk of
death in the drug-treated patients of between 1.6 to 1.7 times the
risk of death in placebo-treated patients. Over the course of a
typical 10-week controlled trial, the rate of death in drug-treated
patients was about 4.5%, compared to a rate of about 2.6% in the
placebo group. Although the causes of death were varied, most of
the deaths appeared to be either cardiovascular (e.g., heart
failure, sudden death) or infectious (e.g., pneumonia) in
nature.</span></p>
<p><span class="Bold">Observational studies suggest that, similar
to atypical antipsychotic drugs, treatment with conventional
antipsychotic drugs may increase mortality. The extent to which the
findings of increased mortality in observational studies may be
attributed to the antipsychotic drug as opposed to some
characteristic(s) of the patients is not clear. FANAPT is not
approved for the treatment of patients with Dementia-Related
Psychosis.</span> <span class="Bold Italics">[see Warnings and
Precautions <a href=
"#d4493060-3bd6-11dejt-5-1">(5.1)</a>]</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a>
<div id="Highlights" class=" Highlights toggle-content closed">
<div class="HighlightsDisclaimer"><span class="Bold">These
highlights do not include all the information needed to use FANAPT
safely and effectively. See full prescribing information for
FANAPT.<br>
FANAPT<span class="Sup">®</span> (iloperidone) tablets<br>
Initial U.S. Approval: 2009</span></div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY
IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS<br>
<span class="Italics"><a href="#a687-0002a5d5c51bjt-bw">See full
prescribing information for complete boxed warning.</a></span><br>
Elderly patients with dementia-related psychosis treated with
antipsychotic drugs are at an increased risk of death. FANAPT is
not approved for use in patients with dementia-related psychosis.
<a href="#d4493060-3bd6-11dejt-5-1">(5.1)</a></span></h1>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FANAPT is an atypical antipsychotic agent
indicated for the treatment of schizophrenia in adults. <a href=
"#cf1996c0-3b40-11dejt-1">(1)</a> Efficacy was established in two
short-term (4-and 6-week) placebo-and active-controlled studies of
adult patients with schizophrenia. <a href=
"#e9b08040-3e5e-11dejt-14">(14)</a> In choosing among treatments,
prescribers should consider the ability of FANAPT to prolong the QT
interval and the use of other drugs first. Prescribers should also
consider the need to titrate FANAPT slowly to avoid orthostatic
hypotension, which may lead to delayed effectiveness compared to
some other drugs that do not require similar titration.</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">The recommended target dosage of FANAPT
tablets is 12 to 24 mg/day administered twice daily. This target
dosage range is achieved by daily dosage adjustments, alerting
patients to symptoms of orthostatic hypotension, starting at a dose
of 1 mg twice daily, then moving to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg,
and 12 mg twice daily on days 2, 3, 4, 5, 6, and 7 respectively, to
reach the 12 mg/day to 24 mg/day dose range. FANAPT can be
administered without regard to meals. <a href=
"#a7d92600-3b42-11dejt-2-1">(2.1)</a></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg
tablets. <a href="#ad5c-0002a5d5c51bjt-3">(3)</a></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">Known hypersensitivity to FANAPT or to any
components in the formulation. <a href=
"#a352-0002a5d5c51bjt-4">(4)</a></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul>
<li><span class="Italics">Elderly patients with dementia-related
psychosis</span> who are treated with atypical antipsychotic drugs
are at an increased risk of death and cerebrovascular-related
adverse events, including stroke. <a href=
"#d4493060-3bd6-11dejt-5-1">(5.1)</a></li>
<li><span class="Italics">QT prolongation:</span> Prolongs QT
interval and may be associated with arrhythmia and sudden
death—consider using other antipsychotics first. Avoid use of
FANAPT in combination with other drugs that are known to prolong
QTc; use caution and consider dose modification when prescribing
FANAPT with other drugs that inhibit FANAPT metabolism. Monitor
serum potassium and magnesium in patients at risk for electrolyte
disturbances. <a href="#cf1996c0-3b40-11dejt-1">(1</a>, <a href=
"#a260-0002a5d5c51bjt-5-2">5.2</a>, <a href=
"#b9ca-0002a5d5c51bjt-7-1">7.1</a>, <a href=
"#bf4d-0002a5d5c51bjt-7-3">7.3</a>, <a href=
"#a0d6-0002a5d5c51bjt-12-3">12.3)</a></li>
<li><span class="Italics">Neuroleptic Malignant Syndrome:</span>
Manage with immediate discontinuation of drug and close monitoring.
<a href="#a21d-0002a5d5c51bjt-5-3">(5.3)</a></li>
<li><span class="Italics">Tardive dyskinesia:</span> Discontinue if
clinically appropriate. <a href=
"#aa81b7e0-3bde-11dejt-5-4">(5.4)</a></li>
<li><span class="Italics">Hyperglycemia and diabetes
mellitus:</span> Monitor glucose regularly in patients at risk for
diabetes. <a href="#adbe-0002a5d5c51bjt-5-5">(5.5)</a></li>
<li><span class="Italics">Seizures:</span> Use cautiously in
patients with a history of seizures or with conditions that lower
seizure threshold. <a href=
"#a619-0002a5d5c51bjt-5-7">(5.7)</a></li>
<li><span class="Italics">Orthostatic hypotension:</span>
Dizziness, tachycardia, and syncope can occur with standing.
<a href="#aa57-0002a5d5c51bjt-5-8">(5.8)</a></li>
<li><span class="Italics">Leukopenia, Neutropenia, and
Agranulocytosis</span> have been reported with antipsychotics.
Patients with a pre-existing low white blood cell count (WBC) or a
history of leukopenia/neutropenia should have their complete blood
count (CBC) monitored frequently during the first few months of
therapy and should discontinue FANAPT at the first sign of a
decline in WBC in the absence of other causative factors. <a href=
"#a5f1-0002a5d5c51bjt-5-9">(5.9)</a></li>
<li><span class="Italics">Suicide:</span> Close supervision of high
risk patients. <a href="#be0769c0-3be5-11dejt-5-13">(5.13)</a></li>
<li><span class="Italics">Priapism:</span> Cases have been reported
in association with FANAPT treatment. <a href=
"#bd19-0002a5d5c51bjt-5-14">(5.14)</a></li>
<li><span class="Italics">Potential for cognitive and motor
impairment:</span> Use caution when operating machinery. <a href=
"#aa3dfe80-3be6-11dejt-5-15">(5.15)</a></li>
<li>See Full Prescribing Information for additional <span class=
"Italics"><a href="#c6ca9960-3bd6-11dejt-5">WARNINGS and
PREACUTIONS</a></span>.</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Commonly observed adverse reactions
(incidence ≥5% and two-fold greater than placebo) were: dizziness,
dry mouth, fatigue, nasal congestion, orthostatic hypotension,
somnolence, tachycardia, and weight increased. <a href=
"#bb0d-0002a5d5c51bjt-6-1">(6.1)</a></p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED
ADVERSE REACTIONS, contact Vanda Pharmaceuticals at 1-888-49VANDA
(1-888-498-2632) or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.</span></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<ul>
<li>The dose of FANAPT should be reduced in patients
co-administered a strong CYP2D6 or CYP3A4 inhibitor. <a href=
"#a014-0002a5d5c51bjt-2-2">(2.2</a>, <a href=
"#b9ca-0002a5d5c51bjt-7-1">7.1)</a></li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC
POPULATIONS</span></h1>
<div>
<ul>
<li>Pregnancy: No human or animal data. Use only if clearly needed.
<a href="#b1fb-0002a5d5c51bjt-8-1">(8.1)</a></li>
<li>Nursing Mothers: Should not breast feed. <a href=
"#a75b2ae0-3e4c-11dejt-8-3">(8.3)</a></li>
<li>Pediatric Use: Safety and effectiveness not established in
children and adolescents. <a href=
"#b135-0002a5d5c51bjt-8-4">(8.4)</a></li>
<li>Hepatic Impairment: Not recommended for patients with hepatic
impairment. <a href="#aeb1-0002a5d5c51bjt-8-7">(8.7)</a></li>
<li>The dose of FANAPT should be reduced in patients who are poor
metabolizers of CYP2D6. <a href=
"#a0d6-0002a5d5c51bjt-12-3">(12.3)</a></li>
</ul>
</div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING
INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2009</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a>
<div id="Index" class=" Index toggle-content closed">
<h1><a href="#section-1" class="toc">WARNING: INCREASED MORTALITY
IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND
USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND
ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Usual Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage in Special
Populations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Maintenance
Treatment</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Reinitiation of
Treatment in Patients Previously Discontinued</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Switching from Other
Antipsychotics</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND
STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND
PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Increased Risks in
Elderly Patients with Dementia-Related Psychosis</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 QT Prolongation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Neuroleptic Malignant
Syndrome (NMS)</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Tardive
Dyskinesia</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hyperglycemia and
Diabetes Mellitus</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Weight Gain</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Seizures</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Orthostatic Hypotension
and Syncope</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Leukopenia, Neutropenia
and Agranulocytosis</a></h2>
<h2><a href="#section-5.10" class="toc">5.10
Hyperprolactinemia</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Body Temperature
Regulation</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Dysphagia</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Suicide</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Priapism</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Potential for
Cognitive and Motor Impairment</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies
Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential for Other
Drugs to Affect FANAPT</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for FANAPT to
Affect Other Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drugs that Prolong the
QT Interval</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC
POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and
Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Renal
Impairment</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Hepatic
Impairment</a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Smoking Status</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND
DEPENDENCE</a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled
Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human
Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of
Overdose</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL
PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of
Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2
Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3
Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL
TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND
HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING
INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 QT Interval
Prolongation</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Neuroleptic Malignant
Syndrome</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Orthostatic
Hypotension</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Interference with
Cognitive and Motor Performance</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Pregnancy</a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Nursing</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Concomitant
Medication</a></h2>
<h2><a href="#section-16.8" class="toc">17.8 Alcohol</a></h2>
<h2><a href="#section-16.9" class="toc">17.9 Heat Exposure and
Dehydration</a></h2>
<dl class="Footnote">
<dt><a name="footnote-content" href="#footnote-reference-content"
id="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing
information are not listed.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">1 INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="cf1996c0-3b40-11dejt-1" id=
"cf1996c0-3b40-11dejt-1"></a> <a name="section-1" id=
"section-1"></a>
<p class="First">FANAPT<span class="Sup">®</span> tablets are
indicated for the treatment of adults with schizophrenia. Efficacy
was established in two short-term (4-and 6-week) placebo-and
active-controlled studies of adult patients with schizophrenia
<span class="Italics">[see Clinical Studies <a href=
"#e9b08040-3e5e-11dejt-14">(14)</a>]</span>.</p>
<p>When deciding among the alternative treatments available for
this condition, the prescriber should consider the finding that
FANAPT is associated with prolongation of the QTc interval
<span class="Italics">[see Warnings and Precautions <a href=
"#a260-0002a5d5c51bjt-5-2">(5.2)</a>]</span>. Prolongation of the
QTc interval is associated in some other drugs with the ability to
cause torsade de pointes-type arrhythmia, a potentially fatal
polymorphic ventricular tachycardia which can result in sudden
death. In many cases this would lead to the conclusion that other
drugs should be tried first. Whether FANAPT will cause torsade de
pointes or increase the rate of sudden death is not yet known.</p>
<p>Patients must be titrated to an effective dose of FANAPT. Thus,
control of symptoms may be delayed during the first 1 to 2 weeks of
treatment compared to some other antipsychotic drugs that do not
require a similar titration. Prescribers should be mindful of this
delay when selecting an antipsychotic drug for the treatment of
schizophrenia <span class="Italics">[see Dosage and Administration
<a href="#a7d92600-3b42-11dejt-2-1">(2.1)</a> and Clinical Studies
<a href="#e9b08040-3e5e-11dejt-14">(14)</a>]</span>.</p>
<p>The effectiveness of FANAPT in long-term use, that is, for more
than 6 weeks, has not been systematically evaluated in controlled
trials. Therefore, the physician who elects to use FANAPT for
extended periods should periodically re-evaluate the long-term
usefulness of the drug for the individual patient <span class=
"Italics">[see Dosage and Administration <a href=
"#b8ef-0002a5d5c51bjt-2-3">(2.3)</a>]</span>.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">2 DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="a43f-0002a5d5c51bjt-2" id=
"a43f-0002a5d5c51bjt-2"></a> <a name="section-2" id=
"section-2"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"a7d92600-3b42-11dejt-2-1" id="a7d92600-3b42-11dejt-2-1"></a>
<a name="section-2.1" id="section-2.1"></a>
<h2>2.1 Usual Dose</h2>
<p class="First">FANAPT must be titrated slowly from a low starting
dose to avoid orthostatic hypotension due to its alpha-adrenergic
blocking properties. The recommended starting dose for FANAPT
tablets is 1 mg twice daily. Increases to reach the target dose
range of 6-12 mg twice daily may be made with daily dosage
adjustments to 2 mg twice daily, 4 mg twice daily, 6 mg twice
daily, 8 mg twice daily, 10 mg twice daily, and 12 mg twice daily
on days 2, 3, 4, 5, 6, and 7, respectively. Efficacy was
demonstrated with FANAPT in a dose range of 6 to 12 mg twice daily.
Prescribers should be mindful of the fact that patients need to be
titrated to an effective dose of FANAPT. Thus, control of symptoms
may be delayed during the first 1 to 2 weeks of treatment compared
to some other antipsychotic drugs that do not require similar
titration. Prescribers should also be aware that some adverse
effects associated with FANAPT use are dose related.</p>
<p>The maximum recommended dose is 12 mg twice daily (24 mg/day);
FANAPT doses above 24 mg/day have not been systematically evaluated
in the clinical trials.</p>
<p>FANAPT can be administered without regard to meals.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a014-0002a5d5c51bjt-2-2" id="a014-0002a5d5c51bjt-2-2"></a>
<a name="section-2.2" id="section-2.2"></a>
<h2>2.2 Dosage in Special Populations</h2>
<p class="First">Dosage adjustments are not routinely indicated on
the basis of age, gender, race, or renal impairment status
<span class="Italics">[see Use in Specific Populations <a href=
"#a5dcabc0-3e4d-11dejt-8-6">(8.6</a>, <a href=
"#aeb1-0002a5d5c51bjt-8-7">8.7)</a>]</span>.</p>
<p><span class="Bold Italics">Dosage adjustment for patients taking
FANAPT concomitantly with potential CYP2D6 inhibitors:</span><br>
FANAPT dose should be reduced by one-half when administered
concomitantly with strong CYP2D6 inhibitors such as fluoxetine or
paroxetine. When the CYP2D6 inhibitor is withdrawn from the
combination therapy, FANAPT dose should then be increased to where
it was before <span class="Italics">[see Drug Interactions <a href=
"#b9ca-0002a5d5c51bjt-7-1">(7.1)</a>]</span>.</p>
<p><span class="Bold Italics">Dosage adjustment for patients taking
FANAPT concomitantly with potential CYP3A4 inhibitors:</span><br>
FANAPT dose should be reduced by one-half when administered
concomitantly with strong CYP3A4 inhibitors such as ketoconazole or
clarithromycin. When the CYP3A4 inhibitor is withdrawn from the
combination therapy, FANAPT dose should be increased to where it
was before <span class="Italics">[see Drug Interactions <a href=
"#b9ca-0002a5d5c51bjt-7-1">(7.1)</a>]</span>.</p>
<p><span class="Bold Italics">Dosage adjustment for patients taking
FANAPT who are poor metabolizers of CYP2D6:</span></p>
<p>FANAPT dose should be reduced by one-half for poor metabolizers
of CYP2D6 [<span class="Italics">see Pharmacokinetics
(12.3)]</span>.</p>
<p><span class="Bold Italics">Hepatic Impairment:</span> FANAPT is
not recommended for patients with hepatic impairment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"b8ef-0002a5d5c51bjt-2-3" id="b8ef-0002a5d5c51bjt-2-3"></a>
<a name="section-2.3" id="section-2.3"></a>
<h2>2.3 Maintenance Treatment</h2>
<p class="First">Although there is no body of evidence available to
answer the question of how long the patient treated with FANAPT
should be maintained, it is generally recommended that responding
patients be continued beyond the acute response. Patients should be
periodically reassessed to determine the need for maintenance
treatment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"b818-0002a5d5c51bjt-2-4" id="b818-0002a5d5c51bjt-2-4"></a>
<a name="section-2.4" id="section-2.4"></a>
<h2>2.4 Reinitiation of Treatment in Patients Previously
Discontinued</h2>
<p class="First">Although there are no data to specifically address
re-initiation of treatment, it is recommended that the initiation
titration schedule be followed whenever patients have had an
interval off FANAPT of more than 3 days.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"b863-0002a5d5c51bjt-2-5" id="b863-0002a5d5c51bjt-2-5"></a>
<a name="section-2.5" id="section-2.5"></a>
<h2>2.5 Switching from Other Antipsychotics</h2>
<p class="First">There are no specific data to address how patients
with schizophrenia can be switched from other antipsychotics to
FANAPT or how FANAPT can be used concomitantly with other
antipsychotics. Although immediate discontinuation of the previous
antipsychotic treatment may be acceptable for some patients with
schizophrenia, more gradual discontinuation may be most appropriate
for others. In all cases, the period of overlapping antipsychotic
administration should be minimized.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43678-2"><a name="ad5c-0002a5d5c51bjt-3" id=
"ad5c-0002a5d5c51bjt-3"></a> <a name="section-3" id=
"section-3"></a>
<p class="First">FANAPT tablets are available in the following
strengths: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg.</p>
<p>The tablets are white, round, flat, beveled-edged and identified
with a logo “<img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-1.jpg"
alt="Logo">” debossed on one side and tablet strength “1”, “2”,
“4”, “6”, “8”, “10”, or “12” debossed on the other side.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">4 CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="a352-0002a5d5c51bjt-4" id=
"a352-0002a5d5c51bjt-4"></a> <a name="section-4" id=
"section-4"></a>
<p class="First">FANAPT is contraindicated in individuals with a
known hypersensitivity reaction to the product. Reactions have
included pruritus and urticaria.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">5 WARNINGS AND PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43685-7"><a name="c6ca9960-3bd6-11dejt-5" id=
"c6ca9960-3bd6-11dejt-5"></a> <a name="section-5" id=
"section-5"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"d4493060-3bd6-11dejt-5-1" id="d4493060-3bd6-11dejt-5-1"></a>
<a name="section-5.1" id="section-5.1"></a>
<h2>5.1 Increased Risks in Elderly Patients with Dementia-Related
Psychosis</h2>
<p class="First"><span class="Bold">Increased Mortality</span></p>
<p><span class="Bold">Elderly patients with dementia-related
psychosis treated with atypical antipsychotic drugs are at an
increased risk of death compared to placebo. FANAPT is not approved
for the treatment of patients with dementia-related psychosis
<span class="Italics">[see <a href="#a687-0002a5d5c51bjt-bw">Boxed
Warning</a>]</span>.</span></p>
<p><span class="Bold">Cerebrovascular Adverse Events, Including
Stroke</span></p>
<p>In placebo-controlled trials with risperidone, aripiprazole, and
olanzapine in elderly patients with dementia, there was a higher
incidence of cerebrovascular adverse events (cerebrovascular
accidents and transient ischemic attacks) including fatalities
compared to placebo-treated patients. FANAPT is not approved for
the treatment of patients with dementia-related psychosis
<span class="Italics">[see <a href="#a687-0002a5d5c51bjt-bw">Boxed
Warning</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a260-0002a5d5c51bjt-5-2" id="a260-0002a5d5c51bjt-5-2"></a>
<a name="section-5.2" id="section-5.2"></a>
<h2>5.2 QT Prolongation</h2>
<p class="First">In an open-label QTc study in patients with
schizophrenia or schizoaffective disorder (n=160), FANAPT was
associated with QTc prolongation of 9 msec at an iloperidone dose
of 12 mg twice daily. The effect of FANAPT on the QT interval was
augmented by the presence of CYP450 2D6 or 3A4 metabolic inhibition
(paroxetine 20 mg once daily and ketoconazole 200 mg twice daily,
respectively). Under conditions of metabolic inhibition for both
2D6 and 3A4, FANAPT 12 mg twice daily was associated with a mean
QTcF increase from baseline of about 19 msec.</p>
<p>No cases of torsade de pointes or other severe cardiac
arrhythmias were observed during the pre-marketing clinical
program.</p>
<p>The use of FANAPT should be avoided in combination with other
drugs that are known to prolong QTc including Class 1A (e.g.,
quinidine, procainamide) or Class III (e.g., amiodarone, sotalol)
antiarrhythmic medications, antipsychotic medications (e.g.,
chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin,
moxifloxacin), or any other class of medications known to prolong
the QTc interval (e.g., pentamidine, levomethadyl acetate,
methadone). FANAPT should also be avoided in patients with
congenital long QT syndrome and in patients with a history of
cardiac arrhythmias.</p>
<p>Certain circumstances may increase the risk of torsade de
pointes and/or sudden death in association with the use of drugs
that prolong the QTc interval, including (1) bradycardia; (2)
hypokalemia or hypomagnesemia; (3) concomitant use of other drugs
that prolong the QTc interval; and (4) presence of congenital
prolongation of the QT interval; (5) recent acute myocardial
infarction; and/or (6) uncompensated heart failure.</p>
<p>Caution is warranted when prescribing FANAPT with drugs that
inhibit FANAPT metabolism <span class="Italics">[see Drug
Interaction <a href="#b9ca-0002a5d5c51bjt-7-1">(7.1)</a>]</span>,
and in patients with reduced activity of CYP2D6 <span class=
"Italics">[see Clinical Pharmacology <a href=
"#a0d6-0002a5d5c51bjt-12-3">(12.3)</a>]</span>.</p>
<p>It is recommended that patients being considered for FANAPT
treatment who are at risk for significant electrolyte disturbances
have baseline serum potassium and magnesium measurements with
periodic monitoring. Hypokalemia (and/or hypomagnesemia) may
increase the risk of QT prolongation and arrhythmia. FANAPT should
be avoided in patients with histories of significant cardiovascular
illness, e.g., QT prolongation, recent acute myocardial infarction,
uncompensated heart failure, or cardiac arrhythmia. FANAPT should
be discontinued in patients who are found to have persistent QTc
measurements &gt;500 ms.</p>
<p>If patients taking FANAPT experience symptoms that could
indicate the occurrence of cardiac arrhythmias, e.g., dizziness,
palpitations, or syncope, the prescriber should initiate further
evaluation, including cardiac monitoring.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a21d-0002a5d5c51bjt-5-3" id="a21d-0002a5d5c51bjt-5-3"></a>
<a name="section-5.3" id="section-5.3"></a>
<h2>5.3 Neuroleptic Malignant Syndrome (NMS)</h2>
<p class="First">A potentially fatal symptom complex sometimes
referred to as Neuroleptic Malignant Syndrome (NMS) has been
reported in association with administration of antipsychotic drugs.
Clinical manifestations include hyperpyrexia, muscle rigidity,
altered mental status (including catatonic signs) and evidence of
autonomic instability (irregular pulse or blood pressure,
tachycardia, diaphoresis, and cardiac dysarrhythmia). Additional
signs may include elevated creatine phosphokinase, myoglobinuria
(rhabdomyolysis), and acute renal failure.</p>
<p>The diagnostic evaluation of patients with this syndrome is
complicated. In arriving at a diagnosis, it is important to
identify cases in which the clinical presentation includes both
serious medical illness (e.g., pneumonia, systemic infection, etc.)
and untreated or inadequately treated extrapyramidal signs and
symptoms (EPS). Other important considerations in the differential
diagnosis include central anticholinergic toxicity, heat stroke,
drug fever, and primary central nervous system (CNS) pathology.</p>
<p>The management of this syndrome should include: (1) immediate
discontinuation of the antipsychotic drugs and other drugs not
essential to concurrent therapy, (2) intensive symptomatic
treatment and medical monitoring, and (3) treatment of any
concomitant serious medical problems for which specific treatments
are available. There is no general agreement about specific
pharmacological treatment regimens for NMS.</p>
<p>If a patient requires antipsychotic drug treatment after
recovery from NMS, the potential reintroduction of drug therapy
should be carefully considered. The patient should be carefully
monitored, since recurrences of NMS have been reported.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"aa81b7e0-3bde-11dejt-5-4" id="aa81b7e0-3bde-11dejt-5-4"></a>
<a name="section-5.4" id="section-5.4"></a>
<h2>5.4 Tardive Dyskinesia</h2>
<p class="First">Tardive dyskinesia is a syndrome consisting of
potentially irreversible, involuntary, dyskinetic movements, which
may develop in patients treated with antipsychotic drugs. Although
the prevalence of the syndrome appears to be highest among the
elderly, especially elderly women, it is impossible to rely on
prevalence estimates to predict, at the inception of antipsychotic
treatment, which patients are likely to develop the syndrome.
Whether antipsychotic drug products differ in their potential to
cause tardive dyskinesia is unknown.</p>
<p>The risk of developing tardive dyskinesia and the likelihood
that it will become irreversible are believed to increase as the
duration of treatment and the total cumulative dose of
antipsychotic administered increases. However, the syndrome can
develop, although much less commonly, after relatively brief
treatment periods at low doses.</p>
<p>There is no known treatment for established cases of tardive
dyskinesia, although the syndrome may remit, partially or
completely, if antipsychotic treatment is withdrawn. Antipsychotic
treatment itself, however, may suppress (or partially suppress) the
signs and symptoms of the syndrome and thereby may possibly mask
the underlying process. The effect that symptomatic suppression has
upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, FANAPT should be prescribed in a
manner that is most likely to minimize the occurrence of tardive
dyskinesia. Chronic antipsychotic treatment should generally be
reserved for patients who suffer from a chronic illness that (1) is
known to respond to antipsychotic drugs, and (2) for whom
alternative, equally effective, but potentially less harmful
treatments are not available or appropriate. In patients who do
require chronic treatment, the smallest dose and the shortest
duration of treatment producing a satisfactory clinical response
should be sought. The need for continued treatment should be
reassessed periodically.</p>
<p>If signs and symptoms of tardive dyskinesia appear in a patient
on FANAPT, drug discontinuation should be considered. However, some
patients may require treatment with FANAPT despite the presence of
the syndrome.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"adbe-0002a5d5c51bjt-5-5" id="adbe-0002a5d5c51bjt-5-5"></a>
<a name="section-5.5" id="section-5.5"></a>
<h2>5.5 Hyperglycemia and Diabetes Mellitus</h2>
<p class="First">Hyperglycemia, in some cases extreme and
associated with ketoacidosis or hyperosmolar coma or death, has
been reported in patients treated with atypical antipsychotics
including FANAPT. Assessment of the relationship between atypical
antipsychotic use and glucose abnormalities is complicated by the
possibility of an increased background risk of diabetes mellitus in
patients with schizophrenia and the increasing incidence of
diabetes mellitus in the general population. Given these
confounders, the relationship between atypical antipsychotic use
and hyperglycemia-related adverse events is not completely
understood. However, epidemiological studies suggest an increased
risk of treatment-emergent hyperglycemia-related adverse events in
patients treated with the atypical antipsychotics included in these
studies. Because FANAPT was not marketed at the time these studies
were performed, it is not known if FANAPT is associated with this
increased risk. Precise risk estimates for hyperglycemia-related
adverse events in patients treated with atypical antipsychotics are
not available.</p>
<p>Patients with an established diagnosis of diabetes mellitus who
are started on atypical antipsychotics should be monitored
regularly for worsening of glucose control. Patients with risk
factors for diabetes mellitus (e.g., obesity, family history of
diabetes) who are starting treatment with atypical antipsychotics
should undergo fasting blood glucose testing at the beginning of
treatment and periodically during treatment. Any patient treated
with atypical antipsychotics should be monitored for symptoms of
hyperglycemia including polydipsia, polyuria, polyphagia, and
weakness. Patients who develop symptoms of hyperglycemia during
treatment with atypical antipsychotics should undergo fasting blood
glucose testing. In some cases, hyperglycemia has resolved when the
atypical antipsychotic was discontinued; however, some patients
required continuation of antidiabetic treatment despite
discontinuation of the suspect drug.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"d899d6c0-3bdf-11dejt-5-6" id="d899d6c0-3bdf-11dejt-5-6"></a>
<a name="section-5.6" id="section-5.6"></a>
<h2>5.6 Weight Gain</h2>
<p class="First">Based on the pooled data from the four
placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies,
the proportions of patients having a weight gain of ≥ 7% body
weight was 12% for FANAPT 10-16 mg/day, 18% for FANAPT 20-24
mg/day, and 13% for FANAPT (combined doses) versus 4% for placebo.
The mean weight change from baseline to endpoint in the short-term
studies was -0.1 kg for placebo versus 2.0 kg for FANAPT-treated
patients. Across all short- and long-term studies, the overall mean
change from baseline at endpoint was 2.1 kg.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a619-0002a5d5c51bjt-5-7" id="a619-0002a5d5c51bjt-5-7"></a>
<a name="section-5.7" id="section-5.7"></a>
<h2>5.7 Seizures</h2>
<p class="First">In short-term placebo-controlled trials (4- to
6-weeks), seizures occurred in 0.1% (1/1344) of patients treated
with FANAPT compared to 0.3% (2/587) on placebo. As with other
antipsychotics, FANAPT should be used cautiously in patients with a
history of seizures or with conditions that potentially lower the
seizure threshold, e.g., Alzheimer’s dementia. Conditions that
lower the seizure threshold may be more prevalent in a population
of 65 years or older.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"aa57-0002a5d5c51bjt-5-8" id="aa57-0002a5d5c51bjt-5-8"></a>
<a name="section-5.8" id="section-5.8"></a>
<h2>5.8 Orthostatic Hypotension and Syncope</h2>
<p class="First">FANAPT can induce orthostatic hypotension
associated with dizziness, tachycardia, and syncope. This reflects
its alpha1-adrenergic antagonist properties. In double-blind
placebo-controlled short-term studies, where the dose was increased
slowly, as recommended above, syncope was reported in 0.4% (5/1344)
of patients treated with FANAPT, compared with 0.2% (1/587) on
placebo. Orthostatic hypotension was reported in 5% of patients
given 20-24 mg/day, 3% of patients given 10-16 mg/day, and 1% of
patients given placebo. More rapid titration would be expected to
increase the rate of orthostatic hypotension and syncope.</p>
<p>FANAPT should be used with caution in patients with known
cardiovascular disease (e.g., heart failure, history of myocardial
infarction, ischemia, or conduction abnormalities), cerebrovascular
disease, or conditions that predispose the patient to hypotension
(dehydration, hypovolemia, and treatment with antihypertensive
medications). Monitoring of orthostatic vital signs should be
considered in patients who are vulnerable to hypotension.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a5f1-0002a5d5c51bjt-5-9" id="a5f1-0002a5d5c51bjt-5-9"></a>
<a name="section-5.9" id="section-5.9"></a>
<h2>5.9 Leukopenia, Neutropenia and Agranulocytosis</h2>
<p class="First">In clinical trial and postmarketing experience,
events of leukopenia/neutropenia have been reported temporally
related to antipsychotic agents. Agranulocytosis (including fatal
cases) has also been reported.</p>
<p>Possible risk factors for leukopenia/neutropenia include
preexisting low white blood cell count (WBC) and history of drug
induced leukopenia/neutropenia. Patients with a pre-existing low
WBC or a history of drug induced leukopenia/neutropenia should have
their complete blood count (CBC) monitored frequently during the
first few months of therapy and should discontinue FANAPT at the
first sign of a decline in WBC in the absence of other causative
factors.</p>
<p>Patients with neutropenia should be carefully monitored for
fever or other symptoms or signs of infection and treated promptly
if such symptoms or signs occur. Patients with severe neutropenia
(absolute neutrophil count &lt;1000/mm<span class="Sup">3</span>)
should discontinue FANAPT and have their WBC followed until
recovery.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a7566bc0-3be2-11dejt-5-10" id="a7566bc0-3be2-11dejt-5-10"></a>
<a name="section-5.10" id="section-5.10"></a>
<h2>5.10 Hyperprolactinemia</h2>
<p class="First">As with other drugs that antagonize dopamine D2
receptors, FANAPT elevates prolactin levels.</p>
<p>Hyperprolactinemia may suppress hypothalamic GnRH, resulting in
reduced pituitary gonadotropin secretion. This, in turn, may
inhibit reproductive function by impairing gonadalsteroidogenesis
in both female and male patients. Galactorrhea, amenorrhea,
gynecomastia, and impotence have been reported with
prolactin-elevating compounds. Long-standing hyperprolactinemia
when associated with hypogonadism may lead to decreased bone
density in both female and male patients.</p>
<p>Tissue culture experiments indicate that approximately one-third
of human breast cancers are prolactin-dependent <span class=
"Italics">in vitro</span>, a factor of potential importance if the
prescription of these drugs is contemplated in a patient with
previously detected breast cancer. Mammary gland proliferative
changes and increases in serum prolactin were seen in mice and rats
treated with FANAPT <span class="Italics">[see Nonclinical
Toxicology <a href="#b49b-0002a5d5c51bjt-13-1">(13.1)</a>]</span>.
Neither clinical studies nor epidemiologic studies conducted to
date have shown an association between chronic administration of
this class of drugs and tumorigenesis in humans; the available
evidence is considered too limited to be conclusive at this
time.</p>
<p>In a short-term placebo-controlled trial (4-weeks), the mean
change from baseline to endpoint in plasma prolactin levels for the
FANAPT 24 mg/day-treated group was an increase of 2.6 ng/mL
compared to a decrease of 6.3 ng/mL in the placebo-group. In this
trial, elevated plasma prolactin levels were observed in 26% of
adults treated with FANAPT compared to 12% in the placebo group. In
the short-term trials, FANAPT was associated with modest levels of
prolactin elevation compared to greater prolactin elevations
observed with some other antipsychotic agents. In pooled analysis
from clinical studies including longer term trials, in 3210 adults
treated with iloperidone, gynecomastia was reported in 2 male
subjects (0.1%) compared to 0% in placebo-treated patients, and
galactorrhea was reported in 8 female subjects (0.2%) compared to 3
female subjects (0.5%) in placebo-treated patients.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"cb6268a0-3be4-11dejt-5-11" id="cb6268a0-3be4-11dejt-5-11"></a>
<a name="section-5.11" id="section-5.11"></a>
<h2>5.11 Body Temperature Regulation</h2>
<p class="First">Disruption of the body’s ability to reduce core
body temperature has been attributed to antipsychotic agents.
Appropriate care is advised when prescribing FANAPT for patients
who will be experiencing conditions which may contribute to an
elevation in core body temperature, e.g., exercising strenuously,
exposure to extreme heat, receiving concomitant medication with
anticholinergic activity, or being subject to dehydration.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a099-0002a5d5c51bjt-5-12" id="a099-0002a5d5c51bjt-5-12"></a>
<a name="section-5.12" id="section-5.12"></a>
<h2>5.12 Dysphagia</h2>
<p class="First">Esophageal dysmotility and aspiration have been
associated with antipsychotic drug use. Aspiration pneumonia is a
common cause of morbidity and mortality in elderly patients, in
particular those with advanced Alzheimer’s dementia. FANAPT and
other antipsychotic drugs should be used cautiously in patients at
risk for aspiration pneumonia <span class="Italics">[see <a href=
"#a687-0002a5d5c51bjt-bw">Boxed Warning</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"be0769c0-3be5-11dejt-5-13" id="be0769c0-3be5-11dejt-5-13"></a>
<a name="section-5.13" id="section-5.13"></a>
<h2>5.13 Suicide</h2>
<p class="First">The possibility of a suicide attempt is inherent
in psychotic illness, and close supervision of high-risk patients
should accompany drug therapy. Prescriptions for FANAPT should be
written for the smallest quantity of tablets consistent with good
patient management in order to reduce the risk of overdose.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"bd19-0002a5d5c51bjt-5-14" id="bd19-0002a5d5c51bjt-5-14"></a>
<a name="section-5.14" id="section-5.14"></a>
<h2>5.14 Priapism</h2>
<p class="First">Three cases of priapism were reported in the
pre-marketing FANAPT program. Drugs with alpha-adrenergic blocking
effects have been reported to induce priapism. FANAPT shares this
pharmacologic activity. Severe priapism may require surgical
intervention.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"aa3dfe80-3be6-11dejt-5-15" id="aa3dfe80-3be6-11dejt-5-15"></a>
<a name="section-5.15" id="section-5.15"></a>
<h2>5.15 Potential for Cognitive and Motor Impairment</h2>
<p class="First">FANAPT, like other antipsychotics, has the
potential to impair judgment, thinking or motor skills. In
short-term, placebo-controlled trials, somnolence (including
sedation) was reported in 11.9% (104/874) of adult patients treated
with FANAPT at doses of 10 mg/day or greater versus 5.3% (31/587)
treated with placebo. Patients should be cautioned about operating
hazardous machinery, including automobiles, until they are
reasonably certain that therapy with FANAPT does not affect them
adversely.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">6 ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="b929-0002a5d5c51bjt-6" id=
"b929-0002a5d5c51bjt-6"></a> <a name="section-6" id=
"section-6"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"bb0d-0002a5d5c51bjt-6-1" id="bb0d-0002a5d5c51bjt-6-1"></a>
<a name="section-6.1" id="section-6.1"></a>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical
trial of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates
observed in clinical practice. The information below is derived
from a clinical trial database for FANAPT consisting of 2070
patients exposed to FANAPT at doses of 10 mg/day or greater, for
the treatment of schizophrenia. All of these patients who received
FANAPT were participating in multiple-dose clinical trials. The
conditions and duration of treatment with FANAPT varied greatly and
included (in overlapping categories), open-label and double-blind
phases of studies, inpatients and outpatients, fixed-dose and
flexible-dose studies, and short-term and longer-term exposure.</p>
<p>Adverse reactions during exposure were obtained by general
inquiry and recorded by clinical investigators using their own
terminology. Consequently, to provide a meaningful estimate of the
proportion of individuals experiencing adverse reactions, reactions
were grouped in standardized categories using MedDRA
terminology.</p>
<p>The stated frequencies of adverse reactions represent the
proportions of individuals who experienced a treatment-emergent
adverse reaction of the type listed. A reaction was considered
treatment emergent if it occurred for the first time or worsened
while receiving therapy following baseline evaluation.</p>
<p>The information presented in these sections was derived from
pooled data from four placebo-controlled, 4- or 6-week, fixed- or
flexible-dose studies in patients who received FANAPT at daily
doses within a range of 10 to 24 mg (n=874).</p>
<p><span class="Bold">Adverse Reactions Occurring at an Incidence
of 2% or More among FANAPT-Treated Patients and More Frequent than
Placebo</span></p>
<p><a href="#T1">Table 1</a> enumerates the pooled incidences of
treatment-emergent adverse reactions that were spontaneously
reported in four placebo-controlled, 4- or 6-week, fixed- or
flexible-dose studies, listing those reactions that occurred in 2%
or more of patients treated with FANAPT in any of the dose groups,
and for which the incidence in FANAPT-treated patients in any dose
group was greater than the incidence in patients treated with
placebo.</p>
<a name="T1" id="T1"></a>
<div class="scrollingtable">
<table width="750">
<caption><span>Table 1: Treatment-Emergent Adverse Reactions in
Short-Term, Fixed- or Flexible-Dose, Placebo-Controlled Trials in
Adult Patients*</span></caption>
<tfoot>
<tr class="First Last">
<td colspan="4">*Table includes adverse reactions that were
reported in 2% or more of patients in any of the FANAPT dose groups
and which occurred at greater incidence than in the placebo group.
Figures rounded to the nearest integer.</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center" colspan="3"><span class="Bold">Percentage of
Patients Reporting Reaction</span></td>
</tr>
<tr>
<td><span class="Bold">Body System or Organ Class</span></td>
<td align="center"><span class="Bold">Placebo</span></td>
<td align="center"><span class="Bold">FANAPT 10-16
mg/day</span></td>
<td align="center"><span class="Bold">FANAPT 20-24
mg/day</span></td>
</tr>
<tr class="Botrule">
<td>Dictionary-derived Term</td>
<td align="center"><span class="Bold">(N=587)</span></td>
<td align="center"><span class="Bold">(N=483)</span></td>
<td align="center"><span class="Bold">(N=391)</span></td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Body as a Whole</span></td>
</tr>
<tr>
<td>Arthralgia</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td>Fatigue</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
<tr>
<td>Musculoskeletal Stiffness</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td>Weight Increased</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">9</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Cardiac Disorders</span></td>
</tr>
<tr>
<td>Tachycardia</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">12</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Eye Disorders</span></td>
</tr>
<tr>
<td>Vision Blurred</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Gastrointestinal
Disorders</span></td>
</tr>
<tr>
<td>Nausea</td>
<td align="center">8</td>
<td align="center">7</td>
<td align="center">10</td>
</tr>
<tr>
<td>Dry Mouth</td>
<td align="center">1</td>
<td align="center">8</td>
<td align="center">10</td>
</tr>
<tr>
<td>Diarrhea</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">7</td>
</tr>
<tr>
<td>Abdominal Discomfort</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Infections</span></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Nervous System
Disorders</span></td>
</tr>
<tr>
<td>Dizziness</td>
<td align="center">7</td>
<td align="center">10</td>
<td align="center">20</td>
</tr>
<tr>
<td>Somnolence</td>
<td align="center">5</td>
<td align="center">9</td>
<td align="center">15</td>
</tr>
<tr>
<td>Extrapyramidal Disorder</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">4</td>
</tr>
<tr>
<td>Tremor</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td>Lethargy</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Reproductive System</span></td>
</tr>
<tr>
<td>Ejaculation Failure</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Respiratory</span></td>
</tr>
<tr>
<td>Nasal Congestion</td>
<td align="center">2</td>
<td align="center">5</td>
<td align="center">8</td>
</tr>
<tr>
<td>Dyspnea</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Skin</span></td>
</tr>
<tr>
<td>Rash</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td colspan="4"><span class="Bold">Vascular Disorders</span></td>
</tr>
<tr>
<td>Orthostatic Hypotension</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr class="Last">
<td>Hypotension</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">3</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold">Dose-Related Adverse Reactions in Clinical
Trials</span></p>
<p>Based on the pooled data from four placebo-controlled, 4- or
6-week, fixed- or flexible-dose studies, adverse reactions that
occurred with a greater than 2% incidence in the patients treated
with FANAPT, and for which the incidence in patients treated with
FANAPT 20-24 mg/day were twice than the incidence in patients
treated FANAPT 10-16 mg/day were: abdominal discomfort, dizziness,
hypotension, musculoskeletal stiffness, tachycardia, and weight
increased.</p>
<p><span class="Bold">Common and Drug-Related Adverse Reactions in
Clinical Trials</span></p>
<p>Based on the pooled data from four placebo-controlled, 4- or
6-week, fixed- or flexible-dose studies, the following adverse
reactions occurred in ≥5% incidence in the patients treated with
FANAPT and at least twice the placebo rate for at least one dose:
dizziness, dry mouth, fatigue, nasal congestion, somnolence,
tachycardia, orthostatic hypotension, and weight increased.
Dizziness, tachycardia, and weight increased were at least twice as
common on 20-24 mg/day as on 10-16 mg/day.</p>
<p><span class="Bold">Extrapyramidal Symptoms (EPS) in Clinical
Trials</span></p>
<p>Pooled data from the four placebo-controlled, 4- or 6-week,
fixed- or flexible-dose studies provided information regarding
treatment-emergent EPS. Adverse event data collected from those
trials showed the following rates of EPS-related adverse events as
shown in <a href="#T2">Table 2</a>.</p>
<a name="T2" id="T2"></a>
<div class="scrollingtable">
<table width="600">
<caption><span>Table 2: Percentage of EPS Compared to
Placebo</span></caption>
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center"><span class="Bold">Placebo (%)</span></td>
<td align="center"><span class="Bold">FANAPT<br>
10-16 mg / day (%)</span></td>
<td align="center"><span class="Bold">FANAPT<br>
20-24 mg / day (%)</span></td>
</tr>
<tr class="Botrule">
<td><span class="Bold">Adverse Event Term</span></td>
<td align="center"><span class="Bold">(N=587)</span></td>
<td align="center"><span class="Bold">(N=483)</span></td>
<td align="center"><span class="Bold">(N=391)</span></td>
</tr>
<tr class="Botrule">
<td><span class="Bold">All EPS events</span></td>
<td align="center"><span class="Bold">11.6</span></td>
<td align="center"><span class="Bold">13.5</span></td>
<td align="center"><span class="Bold">15.1</span></td>
</tr>
<tr>
<td>Akathisia</td>
<td align="center">2.7</td>
<td align="center">1.7</td>
<td align="center">2.3</td>
</tr>
<tr>
<td>Bradykinesia</td>
<td align="center">0</td>
<td align="center">0.6</td>
<td align="center">0.5</td>
</tr>
<tr>
<td>Dyskinesia</td>
<td align="center">1.5</td>
<td align="center">1.7</td>
<td align="center">1.0</td>
</tr>
<tr>
<td>Dystonia</td>
<td align="center">0.7</td>
<td align="center">1.0</td>
<td align="center">0.8</td>
</tr>
<tr>
<td>Parkinsonism</td>
<td align="center">0</td>
<td align="center">0.2</td>
<td align="center">0.3</td>
</tr>
<tr class="Last">
<td>Tremor</td>
<td align="center">1.9</td>
<td align="center">2.5</td>
<td align="center">3.1</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold">Adverse Reactions Associated with
Discontinuation of Treatment in Clinical Trials</span></p>
<p>Based on the pooled data from four placebo-controlled, 4- or
6-week, fixed- or flexible-dose studies, there was no difference in
the incidence of discontinuation due to adverse events between
FANAPT-treated (5%) and placebo-treated (5%) patients. The types of
adverse events that led to discontinuation were similar for the
FANAPT- and placebo-treated patients.</p>
<p><span class="Bold">Demographic Differences in Adverse Reactions
in Clinical Trials</span></p>
<p>An examination of population subgroups in the four
placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies
did not reveal any evidence of differences in safety on the basis
of age, gender or race <span class="Italics">[see Warnings and
Precautions <a href=
"#d4493060-3bd6-11dejt-5-1">(5.1)</a>]</span>.</p>
<p><span class="Bold">Laboratory Test Abnormalities in Clinical
Trials</span></p>
<p>A between-group comparison of the pooled data from four
placebo-controlled, 4- or 6-week studies, revealed no medically
important differences between FANAPT and placebo in mean change
from baseline to endpoint in routine hematology, urinalysis, or
serum chemistry, including glucose. Similarly, there were no
medically important changes in triglyceride and total cholesterol
measurements (<a href="#T3">Table 3</a>). There were no differences
between FANAPT and placebo in the incidence of discontinuation due
to changes in hematology, urinalysis, or serum chemistry.</p>
<a name="T3" id="T3"></a>
<div class="scrollingtable">
<table width="650">
<caption><span>Table 3: Change in Lipids Compared to
Placebo</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Mean change from<br>
baseline (mg/dL)</span></td>
<td align="center"><span class="Bold">Placebo</span></td>
<td align="center"><span class="Bold">FANAPT 10-16
mg/day</span></td>
<td align="center"><span class="Bold">FANAPT 20-24
mg/day</span></td>
</tr>
<tr class="Botrule">
<td></td>
<td align="center"><span class="Bold">(N=587)</span></td>
<td align="center"><span class="Bold">(N=483)</span></td>
<td align="center"><span class="Bold">(N=391)</span></td>
</tr>
<tr>
<td>Triglycerides</td>
<td align="center">-26.5</td>
<td align="center">-26.5</td>
<td align="center">-8.8</td>
</tr>
<tr class="Last">
<td>Total Cholesterol</td>
<td align="center">-7.7</td>
<td align="center">-3.9</td>
<td align="center">3.9</td>
</tr>
</tbody>
</table>
</div>
<p>In short-term placebo-controlled trials (4- to 6-weeks), there
were 1.0% (13/1342) iloperidone-treated patients with hematocrit at
least one time below the extended normal range during
post-randomization treatment, compared to 0.3% (2/585) on placebo.
The extended normal range for lowered hematocrit was defined in
each of these trials as the value 15% below the normal range for
the centralized laboratory that was used in the trial.</p>
<p><span class="Bold">Other Reactions During the Pre-marketing
Evaluation of FANAPT</span></p>
<p>The following is a list of MedDRA terms that reflect
treatment-emergent adverse reactions in patients treated with
FANAPT at multiple doses ≥ 4 mg/day during any phase of a trial
with the database of 3210 FANAPT-treated patients. All reported
reactions are included except those already listed in <a href=
"#T1">Table 1</a>, or other parts of the <span class=
"Italics">Adverse Reactions <a href=
"#b929-0002a5d5c51bjt-6">(6)</a></span> section, those considered
in the <span class="Italics">Warnings and Precautions <a href=
"#c6ca9960-3bd6-11dejt-5">(5)</a></span>, those reaction terms
which were so general as to be uninformative, reactions reported in
fewer than 3 patients and which were neither serious nor
life-threatening, reactions that are otherwise common as background
reactions, and reactions considered unlikely to be drug related. It
is important to emphasize that, although the reactions reported
occurred during treatment with FANAPT, they were not necessarily
caused by it.</p>
<p>Reactions are further categorized by MedDRA system organ class
and listed in order of decreasing frequency according to the
following definitions: frequent adverse events are those occurring
in at least 1/100 patients (only those not listed in <a href=
"#T1">Table 1</a> appear in this listing); infrequent adverse
reactions are those occurring in 1/100 to 1/1000 patients; rare
events are those occurring in fewer than 1/1000 patients.</p>
<p><span class="Italics">Blood and Lymphatic Disorders:
Infrequent</span> – anemia, iron deficiency anemia; <span class=
"Italics">Rare</span> – leukopenia</p>
<p><span class="Italics">Cardiac Disorders: Frequent</span> –
palpitations; <span class="Italics">Rare</span> – arrhythmia,
atrioventricular block first degree, cardiac failure (including
congestive and acute)</p>
<p><span class="Italics">Ear and Labyrinth Disorders:
Infrequent</span> – vertigo, tinnitus</p>
<p><span class="Italics">Endocrine Disorders: Infrequent</span> –
hypothyroidism</p>
<p><span class="Italics">Eye Disorders: Frequent</span> -
conjunctivitis (including allergic); <span class=
"Italics">Infrequent</span> – dry eye, blepharitis, eyelid edema,
eye swelling, lenticular opacities, cataract, hyperemia (including
conjunctival)</p>
<p><span class="Italics">Gastrointestinal Disorders:
Infrequent</span> – gastritis, salivary hypersecretion, fecal
incontinence, mouth ulceration; <span class="Italics">Rare</span> -
aphthous stomatitis, duodenal ulcer, hiatus hernia,
hyperchlorhydria, lip ulceration, reflux esophagitis,
stomatitis</p>
<p><span class="Italics">General Disorders and Administrative Site
Conditions: Infrequent</span> – edema (general, pitting, due to
cardiac disease), difficulty in walking, thirst; <span class=
"Italics">Rare</span> - hyperthermia</p>
<p><span class="Italics">Hepatobiliary Disorders: Infrequent</span>
– cholelithiasis</p>
<p><span class="Italics">Investigations: Frequent:</span> weight
decreased; <span class="Italics">Infrequent</span> – hemoglobin
decreased, neutrophil count increased, hematocrit decreased</p>
<p><span class="Italics">Metabolism and Nutrition Disorders:
Infrequent</span> – increased appetite, dehydration, hypokalemia,
fluid retention</p>
<p><span class="Italics">Musculoskeletal and Connective Tissue
Disorders: Frequent</span> – myalgia, muscle spasms; <span class=
"Italics">Rare</span> – torticollis</p>
<p><span class="Italics">Nervous System Disorders:
Infrequent</span> –paraesthesia, psychomotor hyperactivity,
restlessness, amnesia, nystagmus; <span class="Italics">Rare</span>
– restless legs syndrome</p>
<p><span class="Italics">Psychiatric Disorders: Frequent</span> –
restlessness, aggression, delusion; <span class=
"Italics">Infrequent</span> – hostility, libido decreased,
paranoia, anorgasmia, confusional state, mania, catatonia, mood
swings, panic attack, obsessive-compulsive disorder, bulimia
nervosa, delirium, polydipsia psychogenic, impulse-control
disorder, major depression</p>
<p><span class="Italics">Renal and Urinary Disorders:
Frequent</span> – urinary incontinence; <span class=
"Italics">Infrequent</span> – dysuria, pollakiuria, enuresis,
nephrolithiasis; <span class="Italics">Rare</span> – urinary
retention, renal failure acute</p>
<p><span class="Italics">Reproductive System and Breast Disorders:
Frequent</span> – erectile dysfunction; <span class=
"Italics">Infrequent</span> – testicular pain, amenorrhea, breast
pain; <span class="Italics">Rare</span> – menstruation irregular,
gynecomastia, menorrhagia, metrorrhagia, postmenopausal hemorrhage,
prostatitis.</p>
<p><span class="Italics">Respiratory, Thoracic and Mediastinal
Disorders: Infrequent</span> – epistaxis, asthma, rhinorrhea, sinus
congestion, nasal dryness; <span class="Italics">Rare</span> – dry
throat, sleep apnea syndrome, dyspnea exertional</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">7 DRUG INTERACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34073-7"><a name="b507-0002a5d5c51bjt-7" id=
"b507-0002a5d5c51bjt-7"></a> <a name="section-7" id=
"section-7"></a>
<p class="First">Given the primary CNS effects of FANAPT, caution
should be used when it is taken in combination with other centrally
acting drugs and alcohol. Due to its α1-adrenergic receptor
antagonism, FANAPT has the potential to enhance the effect of
certain antihypertensive agents.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"b9ca-0002a5d5c51bjt-7-1" id="b9ca-0002a5d5c51bjt-7-1"></a>
<a name="section-7.1" id="section-7.1"></a>
<h2>7.1 Potential for Other Drugs to Affect FANAPT</h2>
<p class="First">Iloperidone is not a substrate for CYP1A1, CYP1A2,
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This
suggests that an interaction of iloperidone with inhibitors or
inducers of these enzymes, or other factors, like smoking, is
unlikely.</p>
<p>Both CYP3A4 and CYP2D6 are responsible for iloperidone
metabolism. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6
(e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination
and cause increased blood levels.</p>
<p><span class="Bold Italics">Ketoconazole:</span>
Co-administration of ketoconazole (200 mg twice daily for 4 days),
a potent inhibitor of CYP3A4, with a 3 mg single dose of
iloperidone to 19 healthy volunteers, ages 18-45, increased the AUC
of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%,
respectively. Iloperidone doses should be reduced by about one-half
when administered with ketoconazole or other strong inhibitors of
CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin,
grapefruit juice) have not been studied. When the CYP3A4 inhibitor
is withdrawn from the combination therapy, the iloperidone dose
should be returned to the previous level.</p>
<p><span class="Bold Italics">Fluoxetine:</span> Co-administration
of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor
of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy
volunteers, ages 29-44, who were classified as CYP2D6 extensive
metabolizers, increased the AUC of iloperidone and its metabolite
P88, by about 2-3 fold, and decreased the AUC of its metabolite P95
by one-half. Iloperidone doses should be reduced by one-half when
administered with fluoxetine. When fluoxetine is withdrawn from the
combination therapy, the iloperidone dose should be returned to the
previous level. Other strong inhibitors of CYP2D6 would be expected
to have similar effects and would need appropriate dose reductions.
When the CYP2D6 inhibitor is withdrawn from the combination
therapy, iloperidone dose could then be increased to the previous
level.</p>
<p><span class="Bold Italics">Paroxetine:</span> Co-administration
of paroxetine (20 mg/day for 5-8 days), a potent inhibitor of
CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily)
to patients with schizophrenia ages 18-65 resulted in increased
mean steady-state peak concentrations of iloperidone and its
metabolite P88, by about 1.6 fold, and decreased mean steady-state
peak concentrations of its metabolite P95 by one-half. Iloperidone
doses should be reduced by one-half when administered with
paroxetine. When paroxetine is withdrawn from the combination
therapy, the iloperidone dose should be returned to the previous
level. Other strong inhibitors of CYP2D6 would be expected to have
similar effects and would need appropriate dose reductions. When
the CYP2D6 inhibitor is withdrawn from the combination therapy,
iloperidone dose could then be increased to previous levels.</p>
<p><span class="Bold Italics">Paroxetine and Ketoconazole:</span>
Co-administration of paroxetine (20 mg once daily for 10 days), a
CYP2D6 inhibitor, and ketoconazole (200 mg twice daily) with
multiple doses of iloperidone (8 or 12 mg twice daily) to patients
with schizophrenia ages 18-65 resulted in a 1.4 fold increase in
steady-state concentrations of iloperidone and its metabolite P88
and a 1.4 fold decrease in the P95 in the presence of paroxetine.
So giving iloperidone with inhibitors of both of its metabolic
pathways did not add to the effect of either inhibitor given alone.
Iloperidone doses should therefore be reduced by about one-half if
administered concomitantly with both a CYP2D6 and CYP3A4
inhibitor.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"b4ff-0002a5d5c51bjt-7-2" id="b4ff-0002a5d5c51bjt-7-2"></a>
<a name="section-7.2" id="section-7.2"></a>
<h2>7.2 Potential for FANAPT to Affect Other Drugs</h2>
<p class="First"><span class="Italics">In vitro</span> studies in
human liver microsomes showed that iloperidone does not
substantially inhibit the metabolism of drugs metabolized by the
following cytochrome P450 isozymes: CYP1A1, CYP1A2, CYP2A6, CYP2B6,
CYP2C8, CYP2C9, or CYP2E1. Furthermore, <span class="Italics">in
vitro</span> studies in human liver microsomes showed that
iloperidone does not have enzyme inducing properties, specifically
for the following cytochrome P450 isozymes: CYP1A2, CYP2C8, CYP2C9,
CYP2C19, CYP3A4 and CYP3A5.</p>
<p><span class="Bold Italics">Dextromethorphan:</span> A study in
healthy volunteers showed that changes in the pharmacokinetics of
dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was
co-administered resulted in a 17% increase in total exposure and a
26% increase in C<span class="Sub">max</span> of dextromethorphan.
Thus, an interaction between iloperidone and other CYP2D6
substrates is unlikely.</p>
<p><span class="Bold Italics">Fluoxetine:</span> A single 3 mg dose
of iloperidone had no effect on the pharmacokinetics of fluoxetine
(20 mg twice daily).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"bf4d-0002a5d5c51bjt-7-3" id="bf4d-0002a5d5c51bjt-7-3"></a>
<a name="section-7.3" id="section-7.3"></a>
<h2>7.3 Drugs that Prolong the QT Interval</h2>
<p class="First">FANAPT should not be used with any other drugs
that prolong the QT interval <span class="Italics">[see Warnings
and Precautions <a href=
"#a260-0002a5d5c51bjt-5-2">(5.2)</a>]</span>.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">8 USE IN SPECIFIC POPULATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43684-0"><a name="e490f980-3e47-11dejt-8" id=
"e490f980-3e47-11dejt-8"></a> <a name="section-8" id=
"section-8"></a>
<div class="Section" data-sectioncode="42228-7"><a name=
"b1fb-0002a5d5c51bjt-8-1" id="b1fb-0002a5d5c51bjt-8-1"></a>
<a name="section-8.1" id="section-8.1"></a>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C</p>
<p>FANAPT caused developmental toxicity, but was not teratogenic,
in rats and rabbits.</p>
<p>In an embryo-fetal development study, pregnant rats were given
4, 16, or 64 mg/kg/day (1.6, 6.5, and 26 times the maximum
recommended human dose [MRHD] of 24 mg/day on a mg/m<span class=
"Sup">2</span> basis) of iloperidone orally during the period of
organogenesis. The highest dose caused increased early intrauterine
deaths, decreased fetal weight and length, decreased fetal skeletal
ossification, and an increased incidence of minor fetal skeletal
anomalies and variations; this dose also caused decreased maternal
food consumption and weight gain.</p>
<p>In an embryo-fetal development study, pregnant rabbits were
given 4, 10, or 25 mg/kg/day (3, 8, and 20 times the MRHD on a
mg/m<span class="Sup">2</span> basis) of iloperidone during the
period of organogenesis. The highest dose caused increased early
intrauterine deaths and decreased fetal viability at term; this
dose also caused maternal toxicity.</p>
<p>In additional studies in which rats were given iloperidone at
doses similar to the above beginning from either pre-conception or
from day 17 of gestation and continuing through weaning, adverse
reproductive effects included prolonged pregnancy and parturition,
increased stillbirth rates, increased incidence of fetal visceral
variations, decreased fetal and pup weights, and decreased
post-partum pup survival. There were no drug effects on the
neurobehavioral or reproductive development of the surviving pups.
No-effect doses ranged from 4 to 12 mg/kg except for the increase
in stillbirth rates which occurred at the lowest dose tested of 4
mg/kg, which is 1.6 times the MRHD on a mg/m2 basis. Maternal
toxicity was seen at the higher doses in these studies.</p>
<p>The iloperidone metabolite P95, which is a major circulating
metabolite of iloperidone in humans but is not present in
significant amounts in rats, was given to pregnant rats during the
period of organogenesis at oral doses of 20, 80, or 200 mg/kg/day.
No teratogenic effects were seen. Delayed skeletal ossification
occurred at all doses. No significant maternal toxicity was
produced. Plasma levels of P95 (AUC) at the highest dose tested
were 2 times those in humans receiving the MRHD of iloperidone.</p>
<p>There are no adequate and well-controlled studies in pregnant
women.</p>
<p>Non-Teratogenic Effects</p>
<p>Neonates exposed to antipsychotic drugs, during the third
trimester of pregnancy are at risk for extrapyramidal and/or
withdrawal symptoms following delivery. There have been reports of
agitation, hypertonia, hypotonia, tremor, somnolence, respiratory
distress and feeding disorder in these neonates. These
complications have varied in severity; while in some cases symptoms
have been self-limited, in other cases neonates have required
intensive care unit support and prolonged hospitalization.</p>
<p>FANAPT should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectioncode="34079-4"><a name=
"bc60-0002a5d5c51bjt-8-2" id="bc60-0002a5d5c51bjt-8-2"></a>
<a name="section-8.2" id="section-8.2"></a>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of FANAPT on labor and delivery in
humans is unknown.</p>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"a75b2ae0-3e4c-11dejt-8-3" id="a75b2ae0-3e4c-11dejt-8-3"></a>
<a name="section-8.3" id="section-8.3"></a>
<h2>8.3 Nursing Mothers</h2>
<p class="First">FANAPT was excreted in milk of rats during
lactation. It is not known whether FANAPT or its metabolites are
excreted in human milk. It is recommended that women receiving
FANAPT should not breast feed.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"b135-0002a5d5c51bjt-8-4" id="b135-0002a5d5c51bjt-8-4"></a>
<a name="section-8.4" id="section-8.4"></a>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric and
adolescent patients have not been established.</p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name=
"c2a93800-3e4c-11dejt-8-5" id="c2a93800-3e4c-11dejt-8-5"></a>
<a name="section-8.5" id="section-8.5"></a>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical Studies of FANAPT in the treatment of
schizophrenia did not include sufficient numbers of patients aged
65 years and over to determine whether or not they respond
differently than younger adult patients. Of the 3210 patients
treated with FANAPT in pre-marketing trials, 25 (0.5%) were ≥65
years old and there were no patients ≥75 years old.</p>
<p>Studies of elderly patients with psychosis associated with
Alzheimer’s disease have suggested that there may be a different
tolerability profile (i.e., increased risk in mortality and
cerebrovascular events including stroke) in this population
compared to younger patients with schizophrenia <span class=
"Italics">[see <a href="#a687-0002a5d5c51bjt-bw">Boxed Warning</a>
and Warnings and Precautions <a href=
"#d4493060-3bd6-11dejt-5-1">(5.1)</a>]</span>. The safety and
efficacy of FANAPT in the treatment of patients with psychosis
associated with Alzheimer’s disease has not been established. If
the prescriber elects to treat such patients with FANAPT, vigilance
should be exercised.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a5dcabc0-3e4d-11dejt-8-6" id="a5dcabc0-3e4d-11dejt-8-6"></a>
<a name="section-8.6" id="section-8.6"></a>
<h2>8.6 Renal Impairment</h2>
<p class="First">Because FANAPT is highly metabolized, with less
than 1% of the drug excreted unchanged, renal impairment alone is
unlikely to have a significant impact on the pharmacokinetics of
FANAPT. Renal impairment (creatinine clearance &lt;30 mL/min) had
minimal effect on maximum plasma concentrations (C<span class=
"Sub">max</span>) of iloperidone (given in a single dose of 3 mg)
and its metabolites P88 and P95 any of the three analytes measured.
AUC<span class="Sub">0–∞</span> was increased by 24%, decreased by
6%, and increased by 52% for iloperidone, P88 and P95,
respectively, in subjects with renal impairment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"aeb1-0002a5d5c51bjt-8-7" id="aeb1-0002a5d5c51bjt-8-7"></a>
<a name="section-8.7" id="section-8.7"></a>
<h2>8.7 Hepatic Impairment</h2>
<p class="First">A study in mild and moderate liver impairment has
not been conducted. FANAPT is not recommended for patients with
hepatic impairment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"d3eda940-3e4f-11dejt-8-8" id="d3eda940-3e4f-11dejt-8-8"></a>
<a name="section-8.8" id="section-8.8"></a>
<h2>8.8 Smoking Status</h2>
<p class="First">Based on <span class="Italics">in vitro</span>
studies utilizing human liver enzymes, FANAPT is not a substrate
for CYP1A2; smoking should therefore not have an effect on the
pharmacokinetics of FANAPT.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42227-9"><a name="ec6d0600-3e4f-11dejt-9" id=
"ec6d0600-3e4f-11dejt-9"></a> <a name="section-9" id=
"section-9"></a>
<div class="Section" data-sectioncode="34085-1"><a name=
"a4a2-0002a5d5c51bjt-9-1" id="a4a2-0002a5d5c51bjt-9-1"></a>
<a name="section-9.1" id="section-9.1"></a>
<h2>9.1 Controlled Substance</h2>
<p class="First">FANAPT is not a controlled substance.</p>
</div>
<div class="Section" data-sectioncode="34086-9"><a name=
"baea-0002a5d5c51bjt-9-2" id="baea-0002a5d5c51bjt-9-2"></a>
<a name="section-9.2" id="section-9.2"></a>
<h2>9.2 Abuse</h2>
<p class="First">FANAPT has not been systematically studied in
animals or humans for its potential for abuse, tolerance, or
physical dependence. While the clinical trials did not reveal any
tendency for drug-seeking behavior, these observations were not
systematic and it is not possible to predict on the basis of this
experience the extent to which a CNS active drug, FANAPT, will be
misused, diverted, and/or abused once marketed. Consequently,
patients should be evaluated carefully for a history of drug abuse,
and such patients should be observed closely for signs of FANAPT
misuse or abuse (e.g. development of tolerance, increases in dose,
drug-seeking behavior).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">10 OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="a3db-0002a5d5c51bjt-10" id=
"a3db-0002a5d5c51bjt-10"></a> <a name="section-10" id=
"section-10"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"bdb7-0002a5d5c51bjt-10-1" id="bdb7-0002a5d5c51bjt-10-1"></a>
<a name="section-10.1" id="section-10.1"></a>
<h2>10.1 Human Experience</h2>
<p class="First">In pre-marketing trials involving over 3210
patients, accidental or intentional overdose of FANAPT was
documented in eight patients ranging from 48 mg to 576 mg taken at
once and 292 mg taken over a three-day period. No fatalities were
reported from these cases. The largest confirmed single ingestion
of FANAPT was 576 mg; no adverse physical effects were noted for
this patient. The next largest confirmed ingestion of FANAPT was
438 mg over a four-day period; extrapyramidal symptoms and a QTc
interval of 507 msec were reported for this patient with no cardiac
sequelae. This patient resumed FANAPT treatment for an additional
11 months. In general, reported signs and symptoms where those
resulting from an exaggeration of the known pharmacological effects
(e.g., drowsiness and sedation, tachycardia and hypotension) of
FANAPT.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a4a1-0002a5d5c51bjt-10-2" id="a4a1-0002a5d5c51bjt-10-2"></a>
<a name="section-10.2" id="section-10.2"></a>
<h2>10.2 Management of Overdose</h2>
<p class="First">There is no specific antidote for FANAPT.
Therefore appropriate supportive measures should be instituted. In
case of acute overdose, the physician should establish and maintain
an airway and ensure adequate oxygenation and ventilation. Gastric
lavage (after intubation, if patient is unconscious) and
administration of activated charcoal together with a laxative
should be considered. The possibility of obtundation, seizures or
dystonic reaction of the head and neck following overdose may
create a risk of aspiration with induced emesis. Cardiovascular
monitoring should commence immediately and should include
continuous ECG monitoring to detect possible arrhythmias. If
antiarrhythmic therapy is administered, disopyramide, procainamide
and quinidine should not be used, as they have the potential for
QT-prolonging effects that might be additive to those of FANAPT.
Similarly, it is reasonable to expect that the alpha-blocking
properties of bretylium might be additive to those of FANAPT,
resulting in problematic hypotension. Hypotension and circulatory
collapse should be treated with appropriate measures such as
intravenous fluids or sympathomimetic agents (epinephrine and
dopamine should not be used, since beta stimulation may worsen
hypotension in the setting of FANAPT-induced alpha blockade). In
cases of severe extrapyramidal symptoms, anticholinergic medication
should be administered. Close medical supervision should continue
until the patient recovers.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">11 DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="fe04e3e0-3e51-11dejt-11" id=
"fe04e3e0-3e51-11dejt-11"></a> <a name="section-11" id=
"section-11"></a>
<p class="First">FANAPT is a psychotropic agent belonging to the
chemical class of piperidinyl-benzisoxazole derivatives. Its
chemical name is
4′-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone
. Its molecular formula is C<span class=
"Sub">24</span>H<span class="Sub">27</span>FN<span class=
"Sub">2</span>O<span class="Sub">4</span> and its molecular weight
is 426.48. The structural formula is:</p>
<div class="Figure"><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-2.jpg"
alt="FANAPT Structural Formula"></div>
<p>Iloperidone is a white to off-white finely crystalline powder.
It is practically insoluble in water, very slightly soluble in 0.1
N HCl and freely soluble in chloroform, ethanol, methanol, and
acetonitrile.</p>
<p>FANAPT tablets are intended for oral administration only. Each
round, uncoated tablet contains 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10
mg, or 12 mg of iloperidone. Inactive ingredients are: lactose
monohydrate, microcrystalline cellulose,
hydroxypropylmethylcellulose, crospovidone, magnesium stearate,
colloidal silicon dioxide, and purified water (removed during
processing). The tablets are white, round, flat, beveled-edged and
identified with a logo “<img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-1.jpg"
alt="Logo">” debossed on one side and tablet strength “1”, “2”,
“4”, “6”, “8”, “10”, or “12” debossed on the other side.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">12 CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="afb9-0002a5d5c51bjt-12" id=
"afb9-0002a5d5c51bjt-12"></a> <a name="section-12" id=
"section-12"></a>
<div class="Section" data-sectioncode="43679-0"><a name=
"a24b-0002a5d5c51bjt-12-1" id="a24b-0002a5d5c51bjt-12-1"></a>
<a name="section-12.1" id="section-12.1"></a>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of FANAPT, as with other
drugs having efficacy in schizophrenia, is unknown. However it is
proposed that the efficacy of FANAPT is mediated through a
combination of dopamine type 2 (D<span class="Sub">2</span>) and
serotonin type 2 (5-HT<span class="Sub">2</span>) antagonisms.</p>
</div>
<div class="Section" data-sectioncode="43681-6"><a name=
"ec2bda20-3e56-11dejt12-2" id="ec2bda20-3e56-11dejt12-2"></a>
<a name="section-12.2" id="section-12.2"></a>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">FANAPT exhibits high (nM) affinity binding to
serotonin 5-HT<span class="Sub">2A</span> and dopamine
D<span class="Sub">2</span> and D<span class="Sub">3</span>
receptors (Ki values of 5.6, 6.3, 7.1 nM, respectively). FANAPT has
moderate affinity for dopamine D<span class="Sub">4</span>,
serotonin 5-HT<span class="Sub">6</span> and 5-HT<span class=
"Sub">7</span>, and norepinephrine NE<span class="Sub">α1</span>
receptors (K<span class="Sub">i</span> values of 25, 43, 22, and 36
nM respectively), and low affinity for the serotonin
5-HT<span class="Sub">1A</span>, dopamine D<span class=
"Sub">1</span>, and histamine H<span class="Sub">1</span> receptors
(K<span class="Sub">i</span> values of 168, 216 and 473 nM,
respectively). FANAPT has no appreciable affinity (K<span class=
"Sub">i</span>&gt;1000 nM) for cholinergic muscarinic receptors.
FANAPT functions as an antagonist at the dopamine D<span class=
"Sub">2</span>, D<span class="Sub">3</span>, serotonin
5-HT<span class="Sub">1A</span> and norepinephrine α<span class=
"Sub">1</span>/α<span class="Sub">2C</span> receptors. The affinity
of the FANAPT metabolite P88 is generally equal or less than that
of the parent compound. In contrast, the metabolite P95 only shows
affinity for 5-HT<span class="Sub">2A</span> (K<span class=
"Sub">i</span> value of 3.91) and the NE<span class=
"Sub">α1A</span>, NE<span class="Sub">α1B</span>, NE<span class=
"Sub">α1D</span>, and NE<span class="Sub">α2C</span> receptors
(K<span class="Sub">i</span> values of 4.7, 2.7, 8.8 and 4.7 nM
respectively).</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name=
"a0d6-0002a5d5c51bjt-12-3" id="a0d6-0002a5d5c51bjt-12-3"></a>
<a name="section-12.3" id="section-12.3"></a>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The observed mean elimination half-lives for
iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are
18, 26 and 23 hours, respectively, and in poor metabolizers (PM)
are 33, 37 and 31 hours, respectively. Steady-state concentrations
are attained within 3-4 days of dosing. Iloperidone accumulation is
predictable from single-dose pharmacokinetics. The pharmacokinetics
of iloperidone is more than dose proportional. Elimination of
iloperidone is mainly through hepatic metabolism involving two P450
isozymes, CYP2D6 and CYP3A4.</p>
<p><span class="Bold Italics">Absorption:</span> Iloperidone is
well absorbed after administration of the tablet with peak plasma
concentrations occurring within 2 to 4 hours; while the relative
bioavailability of the tablet formulation compared to oral solution
is 96%. Administration of iloperidone with a standard high-fat meal
did not significantly affect the C<span class="Sub">max</span> or
AUC of iloperidone, P88, or P95, but delayed T<span class=
"Sub">max</span> by 1 hour for iloperidone, 2 hours for P88 and 6
hours for P95. FANAPT can be administered without regard to
meals.</p>
<p><span class="Bold Italics">Distribution:</span> Iloperidone has
an apparent clearance (clearance / bioavailability) of 47 to 102
L/h, with an apparent volume of distribution of 1340-2800 L. At
therapeutic concentrations, iloperidone and its metabolites are
~95% bound to serum proteins.</p>
<p><span class="Bold Italics">Metabolism and Elimination:</span>
Iloperidone is metabolized primarily by three biotransformation
pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6)
and <span class="Italics">O</span>-demethylation (mediated by
CYP3A4). There are two predominant iloperidone metabolites, P95 and
P88. The iloperidone metabolite P95 represents 47.9% of the AUC of
iloperidone and its metabolites in plasma at steady-state for
extensive metabolizers (EM) and 25% for poor metabolizers (PM). The
active metabolite P88 accounts for 19.5% and 34.0% of total plasma
exposure in EM and PM, respectively.</p>
<p>Approximately 7-10% of Caucasians and 3-8% of Black/African
Americans lack the capacity to metabolize CYP2D6 substrates and are
classified as poor metabolizers (PM), whereas the rest are
intermediate, extensive or ultrarapid metabolizers.
Co-administration of FANAPT with known strong inhibitors of CYP2D6
like fluoxetine results in a 2.3 fold increase in iloperidone
plasma exposure, and therefore one-half of the FANAPT dose should
be administered.</p>
<p>Similarly, PMs of CYP2D6 have higher exposure to iloperidone
compared with EMs and PMs should have their dose reduced by
one-half. Laboratory tests are available to identify CYP2D6
PMs.</p>
<p>The bulk of the radioactive materials were recovered in the
urine (mean 58.2% and 45.1% in EM and PM, respectively), with feces
accounting for 19.9% (EM) to 22.1% (PM) of the dosed
radioactivity.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">13 NONCLINICAL TOXICOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"43680-8"><a name="a459-0002a5d5c51bjt-13" id=
"a459-0002a5d5c51bjt-13"></a> <a name="section-13" id=
"section-13"></a>
<div class="Section" data-sectioncode="34083-6"><a name=
"b49b-0002a5d5c51bjt-13-1" id="b49b-0002a5d5c51bjt-13-1"></a>
<a name="section-13.1" id="section-13.1"></a>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold Italics">Carcinogenesis:</span>
Lifetime carcinogenicity studies were conducted in CD-1 mice and
Sprague Dawley rats. Iloperidone was administered orally at doses
of 2.5, 5.0 and 10 mg/kg/day to CD-1 mice and 4, 8 and 16 mg/kg/day
to Sprague Dawley rats (0.5, 1.0 and 2.0 times and 1.6, 3.2 and 6.5
times, respectively, the maximum recommended human dose [MRHD] of
24 mg/day on a mg/m2 basis). There was an increased incidence of
malignant mammary gland tumors in female mice treated with the
lowest dose (2.5 mg/kg/day) only. There were no treatment-related
increases in neoplasia in rats.</p>
<p>Proliferative and/or neoplastic changes in the mammary gland of
rodents have been observed following the chronic administration of
antipsychotic drugs and are considered to be prolactin mediated.
Mammary gland proliferative changes and increases in serum
prolactin were seen in mice and rats treated with iloperidone.</p>
<p>The iloperidone metabolite P95, which is a major circulating
metabolite of iloperidone in humans but is not present in
significant amounts in mice or rats, was given orally to Wistar
rats for 26 weeks at doses of 50 or 500 mg/kg/day. Although this
study was not adequate for assessment of carcinogenic potential,
proliferative responses were seen in several organs: mammary gland
hyperplasia in males and females, thyroid follicular hyperplasia in
females, ovarian interstitial cell hyperplasia, pituitary cell
proliferation in males, and endocrine pancreas proliferation in
males and females. The above were seen at both doses except for the
ovarian and pancreas effects which were seen at the higher dose
only. Plasma levels of P95 (AUC) at the lower dose were 2.5 times
those in humans receiving the MRHD of iloperidone, but as indicated
above a no-effect dose for the proliferative responses was not
determined. It is not known if these proliferative responses will
progress to neoplasia with longer term treatment.</p>
<p><span class="Bold Italics">Mutagenesis:</span> Iloperidone was
negative in the Ames test and in the <span class="Italics">in
vivo</span> mouse bone marrow and rat liver micronucleus tests.
Iloperidone induced chromosomal aberrations in Chinese Hamster
Ovary (CHO) cells <span class="Italics">in vitro</span> at
concentrations which also caused some cytotoxicity.</p>
<p>The iloperidone metabolite P95 was negative in the Ames test,
the V79 chromosome aberration test, and an <span class="Italics">in
vivo</span> mouse bone marrow micronucleus test.</p>
<p><span class="Bold Italics">Impairment of Fertility:</span>
Iloperidone decreased fertility at 12 and 36 mg/kg in a study in
which both male and female rats were treated. The no-effect dose
was 4 mg/kg, which is 1.6 times the maximum recommended human dose
of 24 mg/day on a mg/m<span class="Sup">2</span> basis.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">14 CLINICAL STUDIES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34092-7"><a name="e9b08040-3e5e-11dejt-14" id=
"e9b08040-3e5e-11dejt-14"></a> <a name="section-14" id=
"section-14"></a>
<p class="First">The efficacy of FANAPT in the treatment of
schizophrenia was supported by two placebo- and active-controlled
short-term (4- and 6-week) trials. Both trials enrolled patients
who met the DSM-III/IV criteria for schizophrenia.</p>
<p>Two instruments were used for assessing psychiatric signs and
symptoms in these studies. The Positive and Negative Syndrome Scale
(PANSS) and Brief Psychiatric Rating Scale (BPRS) are both
multi-item inventories of general psychopathology usually used to
evaluate the effects of drug treatment in schizophrenia.</p>
<p>A 6-week, placebo-controlled trial (n=706) involved two dose
ranges of FANAPT (12-16 mg/day or 20-24 mg/day) compared to placebo
and an active control. This study involved titration of FANAPT
starting at 1 mg twice daily on day 1 and increasing to 2, 4, 6, 8,
10 and 12 mg twice daily on days 2, 3, 4, 5, 6, and 7, as needed.
The primary endpoint was change from baseline on the BPRS total
score at the end of treatment (Day 42). Both the 12-16 mg/day and
the 20-24 mg/day dose ranges of FANAPT were superior to placebo on
the BPRS total score. The active control antipsychotic drug
appeared to be superior to FANAPT in this trial within the first 2
weeks, a finding that may in part be explained by the more rapid
titration that was possible for that drug.</p>
<p>A 4-week, placebo-controlled trial (n=604) involved one fixed
dose of FANAPT (24 mg/day) compared to placebo and an active
control. The titration schedule for this study was similar to that
for the 6-week study. This study involved titration of FANAPT
starting at 1 mg twice daily on day 1 and increasing to 2, 4, 6, 8,
10 and 12 mg twice daily on days 2, 3, 4, 5, 6, and 7. The primary
endpoint was change from baseline on the PANSS total score at the
end of treatment (Day 28). The 24 mg/day FANAPT dose was superior
to placebo in the PANSS total score. FANAPT appeared to have
similar efficacy to the active control drug which also needed a
slow titration to the target dose.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="bb6b-0002a5d5c51bjt-16" id=
"bb6b-0002a5d5c51bjt-16"></a> <a name="section-15" id=
"section-15"></a>
<p class="First">FANAPT tablets are white, round and identified
with a logo “<img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-1.jpg"
alt="Logo">” debossed on one side and tablet strength “1”, “2”,
“4”, “6”, “8”, “10”, or “12” debossed on the other side. Tablets
are supplied in the following strengths and package
configurations:</p>
<div class="scrollingtable">
<table width="600">
<tbody class="Headless">
<tr class="First">
<td align="center"><span class="Bold">Package
Configuration</span></td>
<td align="center"><span class="Bold">Tablet Strength
(mg)</span></td>
<td align="center"><span class="Bold">NDC Code</span></td>
</tr>
<tr>
<td align="center">Bottles of 60</td>
<td align="center">1 mg</td>
<td align="center">43068-101-02</td>
</tr>
<tr>
<td align="center">Bottles of 60</td>
<td align="center">2 mg</td>
<td align="center">43068-102-02</td>
</tr>
<tr>
<td align="center">Bottles of 60</td>
<td align="center">4 mg</td>
<td align="center">43068-104-02</td>
</tr>
<tr>
<td align="center">Bottles of 60</td>
<td align="center">6 mg</td>
<td align="center">43068-106-02</td>
</tr>
<tr>
<td align="center">Bottles of 60</td>
<td align="center">8 mg</td>
<td align="center">43068-108-02</td>
</tr>
<tr>
<td align="center">Bottles of 60</td>
<td align="center">10 mg</td>
<td align="center">43068-110-02</td>
</tr>
<tr>
<td align="center">Bottles of 60</td>
<td align="center">12 mg</td>
<td align="center">43068-112-02</td>
</tr>
<tr class="Last">
<td align="center">Titration Pack</td>
<td align="center">2x1 mg, 2x2 mg, 2x4 mg, 2x6 mg<br>
(Total of 8 tablets)</td>
<td align="center">43068-113-04</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectioncode="44425-7"><a name=
"a4c2-0002a5d5c51bjt-16-1" id="a4c2-0002a5d5c51bjt-16-1"></a>
<a name="section-15.1" id="section-15.1"></a>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store FANAPT tablets at controlled room temperature, 25°C
(77°F); excursions permitted to 15° - 30 °C (59° - 86°F) [See USP
Controlled Room Temperature]. Protect FANAPT tablets from exposure
to light and moisture.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">17 PATIENT COUNSELING INFORMATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34076-0"><a name="ed23f4c0-3e61-11dejt-17" id=
"ed23f4c0-3e61-11dejt-17"></a> <a name="section-16" id=
"section-16"></a>
<p class="First">Physicians are advised to discuss the following
issues with patients for whom they prescribe FANAPT:</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"ae9c-0002a5d5c51bjt-17-1" id="ae9c-0002a5d5c51bjt-17-1"></a>
<a name="section-16.1" id="section-16.1"></a>
<h2>17.1 QT Interval Prolongation</h2>
<p class="First">Patients should be advised to consult their
physician immediately if they feel faint, lose consciousness or
have heart palpitations. Patients should be counseled not to take
FANAPT with other drugs that cause QT interval prolongation
<span class="Italics">[see Warnings and Precautions <a href=
"#a260-0002a5d5c51bjt-5-2">(5.2)</a>]</span>. Patients should be
told to inform physicians that they are taking FANAPT before any
new drug is taken.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ab44-0002a5d5c51bjt-17-2" id="ab44-0002a5d5c51bjt-17-2"></a>
<a name="section-16.2" id="section-16.2"></a>
<h2>17.2 Neuroleptic Malignant Syndrome</h2>
<p class="First">Patients and caregivers should be counseled that a
potentially fatal symptom complex sometimes referred to as NMS has
been reported in association with administration of antipsychotic
drugs. Signs and symptoms of NMS include hyperpyrexia, muscle
rigidity, altered mental status, and evidence of autonomic
instability (irregular pulse or blood pressure, tachycardia,
diaphoresis, and cardiac dysrhythmia) <span class="Italics">[see
Warnings and Precautions <a href=
"#a21d-0002a5d5c51bjt-5-3">(5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"aa14caa0-3e62-11dejt-17-3" id="aa14caa0-3e62-11dejt-17-3"></a>
<a name="section-16.3" id="section-16.3"></a>
<h2>17.3 Orthostatic Hypotension</h2>
<p class="First">Patients should be advised of the risk of
orthostatic hypotension, particularly at the time of initiating
treatment, re-initiating treatment, or increasing the dose
<span class="Italics">[see Warnings and Precautions <a href=
"#aa57-0002a5d5c51bjt-5-8">(5.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"aff7d500-3e64-11dejt-17-4" id="aff7d500-3e64-11dejt-17-4"></a>
<a name="section-16.4" id="section-16.4"></a>
<h2>17.4 Interference with Cognitive and Motor Performance</h2>
<p class="First">Because FANAPT may have the potential to impair
judgment, thinking, or motor skills, patients should be cautioned
about operating hazardous machinery, including automobiles, until
they are reasonably certain that FANAPT therapy does not affect
them adversely <span class="Italics">[see Warnings and Precautions
<a href="#aa3dfe80-3be6-11dejt-5-15">(5.15)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ec32d6a0-3e64-11dejt-17-5" id="ec32d6a0-3e64-11dejt-17-5"></a>
<a name="section-16.5" id="section-16.5"></a>
<h2>17.5 Pregnancy</h2>
<p class="First">Patients should be advised to notify their
physician if they become pregnant or intend to become pregnant
during therapy with FANAPT <span class="Italics">[see Use in
Specific Populations <a href=
"#b1fb-0002a5d5c51bjt-8-1">(8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"b9af-0002a5d5c51bjt-17-6" id="b9af-0002a5d5c51bjt-17-6"></a>
<a name="section-16.6" id="section-16.6"></a>
<h2>17.6 Nursing</h2>
<p class="First">Patients should be advised not to breast-feed an
infant if they are taking FANAPT <span class="Italics">[see Use in
Specific Populations <a href=
"#a75b2ae0-3e4c-11dejt-8-3">(8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"aee0-0002a5d5c51bjt-17-7" id="aee0-0002a5d5c51bjt-17-7"></a>
<a name="section-16.7" id="section-16.7"></a>
<h2>17.7 Concomitant Medication</h2>
<p class="First">Patients should be advised to inform their
physicians if they are taking, or plan to take, any prescription or
over-the-counter drugs, since there is a potential for interactions
<span class="Italics">[see Drug Interactions <a href=
"#b507-0002a5d5c51bjt-7">(7)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"b804-0002a5d5c51bjt-17-8" id="b804-0002a5d5c51bjt-17-8"></a>
<a name="section-16.8" id="section-16.8"></a>
<h2>17.8 Alcohol</h2>
<p class="First">Patients should be advised to avoid alcohol while
taking FANAPT.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"a83a-0002a5d5c51bjt-17-9" id="a83a-0002a5d5c51bjt-17-9"></a>
<a name="section-16.9" id="section-16.9"></a>
<h2>17.9 Heat Exposure and Dehydration</h2>
<p class="First">Patients should be advised regarding appropriate
care in avoiding overheating and dehydration.<br>
<br>
<br></p>
<p>FANAPT is a trademark of Vanda Pharmaceuticals Inc.</p>
<p>Distributed by Vanda Pharmaceuticals Inc. Rockville, MD
20850</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="b253-0002a5d5c51bjt-plp-1" id=
"b253-0002a5d5c51bjt-plp-1"></a> <a name="section-17" id=
"section-17"></a>
<p class="First">Package Label - Principal Display Panel - 1mg
Tablet, 60 Count Commercial Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-3.jpg"
alt=
"Package Label - Principal Display Panel - 1mg Tablet, 60 Count Commercial Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="cad7a6a0-720f-11dejt-plp-2" id=
"cad7a6a0-720f-11dejt-plp-2"></a> <a name="section-18" id=
"section-18"></a>
<p class="First">Package Label - Principal Display Panel - 2mg
Tablet, 60 Count Commercial Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-4.jpg"
alt=
"Package Label - Principal Display Panel - 2mg Tablet, 60 Count Commercial Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="b62d-0002a5d5c51bjt-plp-3" id=
"b62d-0002a5d5c51bjt-plp-3"></a> <a name="section-19" id=
"section-19"></a>
<p class="First">Package Label - Principal Display Panel - 4mg
Tablet, 60 Count Commercial Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-5.jpg"
alt=
"Package Label - Principal Display Panel - 4mg Tablet, 60 Count Commercial Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="d4216200-7219-11dejt-plp-4" id=
"d4216200-7219-11dejt-plp-4"></a> <a name="section-20" id=
"section-20"></a>
<p class="First">Package Label - Principal Display Panel - 6mg
Tablet, Container Labels - 14 Count Sample Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-6.jpg"
alt=
"Package Label - Principal Display Panel - 6mg Tablet, Container Labels - 14 Count Sample Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="a718-0002a5d5c51bjt-plp-5" id=
"a718-0002a5d5c51bjt-plp-5"></a> <a name="section-21" id=
"section-21"></a>
<p class="First">Package Label - Principal Display Panel - 6mg
Tablet, Carton Labels - 14 Count Sample Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-7.jpg"
alt=
"Package Label - Principal Display Panel - 6mg Tablet, Carton Labels - 14 Count Sample Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="a696-0002a5d5c51bjt-plp-6" id=
"a696-0002a5d5c51bjt-plp-6"></a> <a name="section-22" id=
"section-22"></a>
<p class="First">Package Label - Principal Display Panel - 6mg
Tablet, 60 Count Commercial Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-8.jpg"
alt=
"Package Label - Principal Display Panel - 6mg Tablet, 60 Count Commercial Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="b028-0002a5d5c51bjt-plp-7" id=
"b028-0002a5d5c51bjt-plp-7"></a> <a name="section-23" id=
"section-23"></a>
<p class="First">Package Label - Principal Display Panel - 8mg
Tablet, Container Labels - 14 Count Sample Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-9.jpg"
alt=
"Package Label - Principal Display Panel - 8mg Tablet, Container Labels - 14 Count Sample Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="b250-0002a5d5c51bjt-plp-8" id=
"b250-0002a5d5c51bjt-plp-8"></a> <a name="section-24" id=
"section-24"></a>
<p class="First">Package Label - Principal Display Panel - 8mg
Tablet, Carton Labels - 14 Count Sample Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-10.jpg"
alt=
"Package Label - Principal Display Panel - 8mg Tablet, Carton Labels - 14 Count Sample Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="b648-0002a5d5c51bjt-plp-9" id=
"b648-0002a5d5c51bjt-plp-9"></a> <a name="section-25" id=
"section-25"></a>
<p class="First">Package Label - Principal Display Panel - 8mg
Tablet, 60 Count Commercial Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-11.jpg"
alt=
"Package Label - Principal Display Panel - 8mg Tablet, 60 Count Commercial Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="a3d428c0-721a-11dejt-plp-10" id=
"a3d428c0-721a-11dejt-plp-10"></a> <a name="section-26" id=
"section-26"></a>
<p class="First">Package Label - Principal Display Panel - 10mg
Tablet, 60 Count Commercial Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-12.jpg"
alt=
"Package Label - Principal Display Panel - 10mg Tablet, 60 Count Commercial Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="b448-0002a5d5c51bjt-plp-11" id=
"b448-0002a5d5c51bjt-plp-11"></a> <a name="section-27" id=
"section-27"></a>
<p class="First">Package Label - Principal Display Panel - 12mg
Tablet, 60 Count Commercial Bottle</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-13.jpg"
alt=
"Package Label - Principal Display Panel - 12mg Tablet, 60 Count Commercial Bottle"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="a594-0002a5d5c51bjt-plp-12" id=
"a594-0002a5d5c51bjt-plp-12"></a> <a name="section-28" id=
"section-28"></a>
<p class="First">Package Label - Principal Display Panel -
Titration Pack, Professional Sample</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-14.jpg"
alt=
"Package Label - Principal Display Panel - Titration Pack, Professional Sample"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="bf3c2680-721a-11dejt-plp-13" id=
"bf3c2680-721a-11dejt-plp-13"></a> <a name="section-29" id=
"section-29"></a>
<p class="First">Package Label - Principal Display Panel -
Titration Pack</p>
<p><img src=
"image.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&amp;name=fanapt-figure-15.jpg"
alt="Package Label - Principal Display Panel - Titration Pack"></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-101</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">1 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-101-02</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-102</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">2 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-102-02</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-104</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">4 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-104-02</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-106</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">6 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">6</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-106-01</td>
<td class="formItem">1 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem"></td>
<td class="formItem">14 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:43068-106-02</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-108</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">8 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">8</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-108-01</td>
<td class="formItem">1 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem"></td>
<td class="formItem">14 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:43068-108-02</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-110</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">10 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-110-02</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-112</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">12 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">12</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-112-02</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone kit</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43068-113</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:43068-113-03</td>
<td class="formItem">1 in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem"></td>
<td class="formItem">1 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:43068-113-04</td>
<td class="formItem">1 in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem"></td>
<td class="formItem">1 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Quantity of Parts</td>
</tr>
<tr>
<th class="formTitle" width="5" scope="col">Part #</th>
<th class="formTitle" scope="col">Package Quantity</th>
<th class="formTitle" scope="col">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem" width="5"><strong>Part 1</strong></td>
<td class="formItem"></td>
<td class="formItem">2</td>
</tr>
<tr class="formTableRow">
<td class="formItem" width="5"><strong>Part 2</strong></td>
<td class="formItem"></td>
<td class="formItem">2</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem" width="5"><strong>Part 3</strong></td>
<td class="formItem"></td>
<td class="formItem">2</td>
</tr>
<tr class="formTableRow">
<td class="formItem" width="5"><strong>Part 4</strong></td>
<td class="formItem"></td>
<td class="formItem">2</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table cellpadding="5" cellspacing="0" width="100%">
<tbody>
<tr>
<td class="contentTableTitle">Part 1 of 4</td>
</tr>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td></td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">1 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table cellpadding="5" cellspacing="0" width="100%">
<tbody>
<tr>
<td class="contentTableTitle">Part 2 of 4</td>
</tr>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td></td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">2 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table cellpadding="5" cellspacing="0" width="100%">
<tbody>
<tr>
<td class="contentTableTitle">Part 3 of 4</td>
</tr>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td></td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">4 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table cellpadding="5" cellspacing="0" width="100%">
<tbody>
<tr>
<td class="contentTableTitle">Part 4 of 4</td>
</tr>
<tr>
<td class="contentTableTitle"><strong>FANAPT</strong><br>
<span class="contentTableReg">iloperidone tablet</span></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td></td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ILOPERIDONE</strong> (UNII:
VPO7KJ050N) (ILOPERIDONE - UNII:VPO7KJ050N)</td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">6 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong>
(UNII: RFW2ET671P)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong> (UNII:
68401960MK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">6</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Vanda Pharmaceuticals Inc.
(133501556)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="#boxedwarning" target="_blank">Boxed Warnings</a>,
<a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22ILOPERIDONE%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=ILOPERIDONE"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=ILOPERIDONE"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=ILOPERIDONE&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">FANAPT - iloperidone tablet<br>
FANAPT - iloperidone<br></h3>
<h4>Number of versions: 5</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Mar 23, 2011</td>
<td>16 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=50885">download</a></td>
</tr>
<tr>
<td>Dec 7, 2010</td>
<td>14</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=43617">download</a></td>
</tr>
<tr>
<td>Sep 15, 2010</td>
<td>9</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=27938">download</a></td>
</tr>
<tr>
<td>Jan 25, 2010</td>
<td>7</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=15670">download</a></td>
</tr>
<tr>
<td>Oct 2, 2009</td>
<td>6</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=12573">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">FANAPT - iloperidone tablet<br>
FANAPT - iloperidone<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848722">848722</a></td>
<td>iloperidone 1 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848722">848722</a></td>
<td>iloperidone 1 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848726">848726</a></td>
<td>Fanapt 1 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848726">848726</a></td>
<td>iloperidone 1 MG Oral Tablet [Fanapt]</td>
<td>SBD</td>
</tr>
<tr>
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848726">848726</a></td>
<td>Fanapt 1 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848728">848728</a></td>
<td>iloperidone 10 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848728">848728</a></td>
<td>iloperidone 10 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848730">848730</a></td>
<td>Fanapt 10 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>9</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848730">848730</a></td>
<td>iloperidone 10 MG Oral Tablet [Fanapt]</td>
<td>SBD</td>
</tr>
<tr>
<td>10</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848730">848730</a></td>
<td>Fanapt 10 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>11</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848732">848732</a></td>
<td>iloperidone 12 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>12</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848732">848732</a></td>
<td>iloperidone 12 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>13</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848734">848734</a></td>
<td>Fanapt 12 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>14</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848734">848734</a></td>
<td>iloperidone 12 MG Oral Tablet [Fanapt]</td>
<td>SBD</td>
</tr>
<tr>
<td>15</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848734">848734</a></td>
<td>Fanapt 12 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>16</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848736">848736</a></td>
<td>iloperidone 2 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>17</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848736">848736</a></td>
<td>iloperidone 2 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>18</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848738">848738</a></td>
<td>Fanapt 2 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>19</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848738">848738</a></td>
<td>iloperidone 2 MG Oral Tablet [Fanapt]</td>
<td>SBD</td>
</tr>
<tr>
<td>20</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848738">848738</a></td>
<td>Fanapt 2 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>21</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848740">848740</a></td>
<td>iloperidone 4 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>22</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848740">848740</a></td>
<td>iloperidone 4 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>23</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848742">848742</a></td>
<td>Fanapt 4 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>24</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848742">848742</a></td>
<td>iloperidone 4 MG Oral Tablet [Fanapt]</td>
<td>SBD</td>
</tr>
<tr>
<td>25</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848742">848742</a></td>
<td>Fanapt 4 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>26</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848744">848744</a></td>
<td>iloperidone 6 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>27</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848744">848744</a></td>
<td>iloperidone 6 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>28</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848746">848746</a></td>
<td>Fanapt 6 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>29</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848746">848746</a></td>
<td>iloperidone 6 MG Oral Tablet [Fanapt]</td>
<td>SBD</td>
</tr>
<tr>
<td>30</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848746">848746</a></td>
<td>Fanapt 6 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>31</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848748">848748</a></td>
<td>iloperidone 8 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>32</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848748">848748</a></td>
<td>iloperidone 8 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>33</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848750">848750</a></td>
<td>Fanapt 8 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>34</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848750">848750</a></td>
<td>iloperidone 8 MG Oral Tablet [Fanapt]</td>
<td>SBD</td>
</tr>
<tr>
<td>35</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848750">848750</a></td>
<td>Fanapt 8 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>36</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848751">848751</a></td>
<td>{2 (iloperidone 1 MG Oral Tablet) / 2 (iloperidone 2 MG Oral
Tablet) / 2 (iloperidone 4 MG Oral Tablet) / 2 (iloperidone 6 MG
Oral Tablet) } Pack</td>
<td>GPCK</td>
</tr>
<tr class="psn-rxtty">
<td>37</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848752">848752</a></td>
<td>Fanapt Titration Pack</td>
<td>PSN</td>
</tr>
<tr>
<td>38</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848752">848752</a></td>
<td>{2 (iloperidone 1 MG Oral Tablet [Fanapt]) / 2 (iloperidone 2
MG Oral Tablet [Fanapt]) / 2 (iloperidone 4 MG Oral Tablet
[Fanapt]) / 2 (iloperidone 6 MG Oral Tablet [Fanapt]) } Pack
[Fanapt Titration Pack]</td>
<td>BPCK</td>
</tr>
<tr>
<td>39</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=848752">848752</a></td>
<td>Fanapt Titration Pack</td>
<td>SY</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">FANAPT - iloperidone tablet<br>
FANAPT - iloperidone<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFANAPT%20%2D%20Iloperidone%20Tablet%20FANAPT%20%2D%20Iloperidone%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D33f60b40%2D3fca%2D11de%2D8f56%2D0002a5d5c51b%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "FANAPT - iloperidone tablet <br>FANAPT - iloperidone   <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
